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CHAPTER 1 INTRODUCTION
One crucial step in understanding the biological mechanism underlying a disease condition is to capture the relationship between the variants and the disease risk [96]. There
are several publicly available databases contain the disease-associated variants such as
UMD [15], Swiss-Prot [16], SNPedia [25], COSMIC [34], OMIM [44], Clinvar [63], InSiGHT [78], dbSNP [93], MutDB [95], HGMD [99], HGVbaseG2P [104], PharmGKB [105],
BioMuta [115], etc. All these databases are manually curated by human experts. While
this manual curation ensures a high quality of the annotations, the manual extraction of
this type of information from the biomedical literature takes an enormous amount of time
and effort. The current rate with which new variants are published is simply too high for
any manual annotation process. As an additional challenge, despite the HGVS (Human
Genome Variation Society) standard recommendations for the description of the variants,
many variants are still reported in the literature in non-standard formats. A number of
automatic mutation indexing tools have been developed. Such tools process biomedical
literature and produce a list of mutations that appear in these papers. These include
MutationMiner [9], MutationFinder [23], EMU [29], MuteXt [49], Mutation Grab [67],
MEMA [82], etc. The most recent such tool, tmVar 2.0 [114] extracts variants from an
article and normalizes them to their unique dbSNP identifiers. The next step is to develop
software tools to extract variants-disease associations from the biomedical literature. Several methods have been proposed for this purpose such as OSIRIS [17], MuGeX [32],
EnzyMiner [118], the methods proposed by Singhal et al. [96, 97], etc. All these methods have been applied to only the title and the abstract section of biomedical articles.
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However, a comprehensive study showed that a significant number of genetic variants are
only included in the full text and the supplementary materials of the articles [55]. These
will be missed if the variants are only extracted from titles and abstracts. Doughty et
al. [29] also proposed a tool named EMU for extracting the disease-associated mutations
from biomedical literature. Although this tool automatically extracts the mutations and
their corresponding genes from an article, it still requires human curation to discover the
mutation-disease associations.
Here we propose an autoMated pipeline for inferring vAriant-driven Gene PanEls from
the full-length biomedical Literature (MAGPEL) [89]. As the first step, the proposed
framework employs word cloud analysis to identify the variant-relevant articles. The
variant-gene-disease associations are then extracted from these articles. An evidencebased variant-driven gene panel is then generated based on the mined triplet information. A comprehensive validation procedure illustrates the capabilities of the proposed
framework. We validate the proposed variant-driven gene panel by showing their abilities
to predict the patients’ clinical conditions (healthy vs. disease) on multiple independent
validation datasets.
This document is organized as follows. In chapter 2, we first present a survey on the
current publicly available databases and resources for disease-associated variants. Then,
we provide an overview of the existing variant indexing tools that are able to extract variant entities from biomedical text. Chapter 3 focuses on our proposed automated pipeline
for extracting variants from full-length biomedical literature. The detailed explanation of
each step of the proposed pipeline and also the proposed validation analysis are presented
in this chapter. Chapter 4 presents the results and the discussion section is provided in
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chapter 5. Finally, the conclusion and future work are discussed in chapter 6.

4

CHAPTER 2 BACKGROUND AND RELATED WORK
A genetic variant refers to the presence of alterations in the DNA sequences among
individuals within a population. The disease-associated variants and the genetic polymorphisms (not disease-associated variants) are the two main categories of the genetic
variants based on their frequencies within a population. Single-nucleotide polymorphism
(SNP) is the most common type of polymorphism that occurs when one single nucleotide
is replaced with another nucleotide. A disease-associated variant on the other hand refers
to the rare type of variant that increases the risk of developing diseases. There are several forms of genetic variants depending on the changes in the reference sequence such as
insertions, deletions, duplications, etc [101]. The detailed explanations and examples for
each type of variants described on both the DNA level and the protein level are provided
in Tables 1 and 2, respectively.
Table 1: Different types of variants described at the DNA level based on HGVS (Human Genome Variation Society) standard recommendations (https://varnomen.hgvs.
org/recommendations/DNA/).
Type of variant

Definition

Insertion

A sequence change when one or multiple nucleotides are
c.104insT
inserted.
A sequence change when one or multiple nucleotides are deleted. c.104delT

Deletion
Substitution
Duplication
Deletion-insertion
Inversion
Conversion

2.1

A sequence change when one nucleotide is replaced with another
nucleotide.
A sequence change when copy of one or multiple nucleotides are
inserted.
A sequence change when one or multiple nucleotides are
replaced by one or multiple other nucleotides.
A sequence change when multiple nucleotides are replaced by
the reverse complement of the original sequence.
A sequence change when multiple nucleotides are replaced by
multiple nucleotides copied from different positions in the
sequence.

Example

Chromosome
Position
104

Reference
nucleotide(s)
NA

Alternative
nucleotide(s)
T

104

T

NA

c.435C>G

435

C

G

c.64_65dupTT

64_65

NA

TT

c.145_147delinsTGG

145_147

NA

TGG

c.5657_5660inv

5657_5660

TCAG

CTGA

c.732_749con818_835

732_749

NA

NA

Current databases for disease-associated variants

With rapidly evolving sequencing technologies, the number of articles studying genomic variants and their associations with human diseases is dramatically increased [24,
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Table 2: Different types of variants described at the protein level based on HGVS (Human Genome Variation Society) standard recommendations (https://varnomen.hgvs.
org/recommendations/protein/).
Type of variant

Definition

Example

Insertion

A sequence change when one or multiple amino acids are
inserted.
A sequence change when one or multiple amino acids are
deleted.
A sequence change when one amino acid is replaced with
another amino acid.
A sequence change when copy of one or multiple amino acids are
inserted.
A sequence change when one or multiple amino acids are
replaced by one or multiple other amino acids.
A sequence change because of translation shift into another
reading frame.

Deletion
Substitution
Duplication
Deletion-insertion
Frame shift

p.His4_Gln5insAla

Chromosome
Position
4_5

Reference
amino acid(s)
NA

Alternative
amino acid(s)
Ala

p.Trp4del

4

Trp

NA

p.Trp24Cys

24

Trp

Cys

p.Ala3dup

3

NA

Ala

p.Cys28delinsTrpVal

28

NA

TrpVal

p.Arg97ProfsTer23

97

Arg

Pro

124]. Publicly available databases such as SNPedia [25], Clinvar [63], dbSNP [93],
TopoSNP [100], etc. have been developed to aggregate and provide easy access to the
results of these studies. In this section, we provide an overview of such open-access repositories designed specifically for the genomic variants (see Table 3).
Table 3: Summary of the current open-source warehouses providing information about
variants, genes, and disease phenotypes.
Database
dbSNP [93]

Description
Catalog of SNPs

URL
https://www.ncbi.nlm.nih.gov/snp/

PharmGKB [47]

Catalog of human variations and drug responses

https://www.pharmgkb.org/

Ensembl [50]

Catalog of vertebrate genomes

https://ensembl.org

TopoSNP [100]

Catalog of SNPs

http://sts.bioe.uic.edu/toposnp/

COSMIC [34]

Catalog of cancer-associated somatic mutations

https://cancer.sanger.ac.uk/cosmic

SNPedia [25]

Catalog of disease-associated SNPs

https://snpedia.com

SwissVar [119]

Catalog of mutations present in UniProt

https://swissvar.expasy.org

ICGC [123]

Catalog of cancer-associated variants

https://dcc.icgc.org

HGVbaseG2P [104]

Catalog of disease-associated variants

https://www.gwascentral.org

1000 Genomes [74]

Catalog of human variations

https://www.ncbi.nlm.nih.gov/variation/tools/1000genomes/

MoKCa [85]

Catalog of cancer-associated mutations

http://strubiol.icr.ac.uk/extra/mokca/

OMIM [3]

Catalog of disease-associated mendelian mutations

https://omim.org

Clinvar [63]

Catalog of disease-associated variants

https://www.ncbi.nlm.nih.gov/clinvar/

IntOGen-mutations [41]

Catalog of cancer-associated mutations

https://www.intogen.org

BioMuta [28, 115]

Catalog of cancer-associated SNPs

https://hive.biochemistry.gwu.edu/biomuta

CIViC [42]

Catalog of cancer-associated variants

https://civicdb.org/home

LitVar [2]

Catalog of variants and associated genes, diseases and drugs https://www.ncbi.nlm.nih.gov/CBBresearch/Lu/Demo/LitVar/

Established by the National Center for Biotechnology Information (NCBI), dbSNP is
the largest database providing information for the identified single nucleotide variants
(SNPs) [93]. The latest version of dbSNP (build 154) which was released in April 2020
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contains over two billion submitted SNP and 729,491,867 reference SNP records. For each
SNP record, dbSNP provides a wide range of information described as follows:
• The clinical significance tab provides a list of diseases known to be associated with
the queried SNP derived from ClinVar [63].
• The frequency tab displays a table of the reference and the alternative allele frequencies for the queried SNP obtained from biomedical articles.
• The aliases tab displays all the different HGVS entries such as DNA and protein level
HGVS format of the queried SNP.
• The submissions tab shows a list of variants originally were submitted to dbSNP and
now support the queried SNP.
• The history tab displays all the associated RefSNPs published in the previous dbSNP
versions.
• The publications tab displays all the PubMed articles that mention the queried SNP.
The Human Genome Variation database of Genotype to Phenotype (HGVbaseG2P) is
a website providing information for the identified SNPs and their related diseases [104].
For each SNP record, this database provides the general genomic information as well as
the corresponding hyperlinks to OMIM [3], SNPedia [25], and dbSNP [93] databases for
further information.
The disease-SNP association database named SNPedia [25] provides a summary of
the existing knowledge about the disease-associated SNPs through a user-friendly webbased tool. For each queried SNP, in addition to the basic genomic information such
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as chromosome number, position, alleles, etc. this database provides hyperlinks to the
external databases such as dbSNP [93], ClinGen [83], etc. The list of articles that have
cited the queried SNP is also available through SNPedia.
ClinVar [63] is one of the largest publicly available web-based tools for human genetic
variants. This database was launched in 2013 by the National Center for Biotechnology
Information, National Institutes of Health (NIH). The variants are submitted to ClinVar
by the research and clinical laboratories and expert groups. For each variant record, in
addition to the basic genomic properties, the corresponding ClinVar web page provides
the following information:

• The Conditions tab provides information and evidence regarding the diseases known
to be associated with the queried variant.
• The Gene(s) tab shows the region overview of the variant’s corresponding gene as
well as a hyperlink to the gene’s corresponding page in the OMIM [3] database.

Several databases have been designed and implemented specifically for cancer-associated
variants. These includes BioMuta [28, 115], COSMIC [34], CIViC [42] and ICGC [122].
The Catalogue Of Somatic Mutations In Cancer (COSMIC [34]) is the largest database
contains cancer-related somatic mutations. The two main resources feed into this database
are i) manually curation of the scientific literature and ii) the Cancer Genome Project
(CGP) at the Sanger Institute UK. For each mutation record, COSMIC provides the following information:
• The Overview tab provides a summary of the general genomic properties of the
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queried mutation such as chromosome, position, reference, and alternative alleles
and the corresponding gene.
• The Tissue distribution tab shows the top 5 tissue types with the highest number of
identified mutated samples.
• The Samples tab displays all the available information for the mutated samples such
as tissue, histology, zygosity, and also reference articles.
• The Pathway affected tab shows a list of pathways known to be affected by the queried
mutation.
• The References tab shows a list of publications providing evidence and information
for the queried mutation.
The International Cancer Genome Consortium (ICGC) data portal [122] is an advanced
web-based tool providing comprehensive information for the mutations identified in several major cancer types. This database is a collection of over 81 million cancer-associated
mutations collected from 86 different projects. For each mutation record, ICGC provides a
wide range of information such as:
• The Summary tab summarizes all the available information for the queried mutations
such as genomic properties, cancer distribution, etc.
• The Clinical evidence tab shows a table with all the available clinical studies related to
the queried mutation obtained from the Clinical Interpretation of Variants in Cancer
(CIViC) database [42].
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• The Protein tab shows the distribution of the identified mutations along with the
corresponding protein sequences.
• The Genome viewer tab provides the region overview of the corresponding gene.
BioMuta [28, 115] is another web-based tool designed specifically for cancer-associated
SNPs. This tool collects data from different resources such as UniProt [8], COSMIC [34],
IntOGen [41], ClinVar [63], TCGA [103] and ICGC [122]. BioMuta provides the list of the
most common variants identified for each cancer type. The general page layout provided
by BioMuta for a queried gene contains information for all the identified Nonsynonymous
single-nucleotide variations (nsSNVs) such as the genomic coordinates, the identified cancer types, and the supporting articles.
Clinical Interpretation of Variants in Cancer (CIViC [42]) is another open access resource for the cancer-associated variants. For each queried gene, this database provides
detailed information about all the identified cancer-related somatic mutations. These include the variant genomic coordinates and the corresponding hyperlinks to the external
databases such as COSMIC [34], ClinVar [63], and dbSNP [93].
Finally, PharmGKB [47] provides association information regarding human genetic
variations and drug responses. The main goal of this database is to integrate available
knowledge regarding human genetic variations and their effects on drug responses. For
each queried gene, this database summarizes all the genomic variants associated with the
queried gene, the drug it interacts with as well as hyperlinks to the corresponding evidence, studies, and articles.
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2.2

Current automatic variant indexing tools

The current database curators are not able to keep track of all the new annotated variants because the current rate with which new variants are published is too high. In order
to keep up with the new variants being published in the literature, a number of automation
tools for indexing mutations from the biomedical text have been developed [53]. These
tools use different computational algorithms such as conditional random field (CRF), regular expressions (RegExp), machine learning, and graph theory to identify variant-genotypephenotype associations from biomedical literature. In the following, we review some of
these methods focusing on the underlying concept used, primary features, availability, and
key advantages (see Table 4).
Table 4: List of existing text-mining variant extraction methods based on the criteria related to the computational models and implementations.
Method
VTag [73]

Concept used
Conditional random field

Availability Language
N/A
N/A

Year
2004

MuteXt [49]

Regular expressions

Standalone

Python

2004

MEMA [82]

Regular expressions

N/A

N/A

2004

MutationMiner [9]

Regular expressions

N/A

N/A

2006

YIP [119]

Regular expressions

N/A

N/A

2007

MuGeX [32]

Regular expressions

N/A

N/A

2007

Mutation GraB [67]

Regular expressions

N/A

N/A

2007

MutationFinder [23] Regular expressions

Standalone

Python, Perl, Java

2007

EMU [29]

Regular expressions

Standalone

Perl

2011

tmVar [112]

Conditional random field

Standalone

Java

2013

tmVar 2.0 [114]

Conditional random field

Standalone

Java

2017

A number of methods have been proposed for the variant entity extraction from text
using a machine learning technique named conditional random fields (CRF) [62]. The
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main characteristics of these methods are summarized in Table 5.
Table 5: Summary of the important characteristics of the reviewed conditional random
field (CRF) approaches for variant extraction from biomedical text.
Method
VTag [73]

Type of mutation
Protein, DNA

Gene/protein identification Disease identification
7
7

RSID normalization
3

tmVar [114]

Protein, DNA, SNP 3

7

7

tmVar 2.0 [114]

Protein, DNA, SNP 3

7

3

McDonald et al. [73] proposed an automated variant extraction tool named VTag in
2004. The proposed CRF-based method extracts the sequence variations mentioned in the
cancer-related articles and further maps them to their corresponding dbSNP identifiers. On
a corpus of 105 cancer-related abstracts, the method achieves 79% recall, 85% precision,
and 82% F-measure score.
Wei et al. [112] proposed another CRF-based model named tmVar to extract the mentioned variants from biomedical articles. The proposed model considers each component
of a variant entity as one label and the variant itself as a sequence of labels. For example, tmVar retrieves each component of c.607_608insACA mutation separately (eg. “ins”
as the mutation type, “CAA” as the alternative sequence and “607_608” as the position).
Identification of a wide range of mutation types (DNA, protein, and SNP) is one of the key
advantages of tmVar. In 2017, the second version of this tool named tmVar 2.0 [114] was
proposed. This tool first extracts the variant entities using the same algorithm as tmVar
and further normalizes them to their unique dbSNP identifiers.
Several methods have been proposed to extract variants from biomedical literature
using the standard regular expressions algorithm (RegExp). Here, we review several of
these methods which are listed in Table 6.
Horn et al. [49] introduced MuteXt for extracting point mutations from biomedical
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Table 6: Summary of the important characteristics of the reviewed regular expressions
(RegExp) approaches for variant extraction from biomedical text.
Method
MuteXt [49]

Type of mutation Gene/protein identification Disease identification
Protein, DNA
3
7

RSID normalization
7

MEMA [82]

Protein, DNA

3

7

7

MutationMiner [9]

Protein

7

7

7

MuGeX [32]

Protein

3

3

7

MutationFinder [23] Protein

7

7

7

Mutation GraB [67]

Protein

3

7

7

EMU [29]

Protein, DNA

3

7

7

literature in 2004. MuteXt uses regular expressions (RegExp) with a pattern starts with
one amino acid that can be one- or three-letter term, followed by a number, and ends
with another amino acid followed by the format of the first one (e.g. G12D or Gly12Asp).
MuteXt is also able to extract protein names and species names from an article. The
identified mutation-protein pairs are then validated in two different ways: i) sequence
filtering and ii) distance filtering. The sequence filtering checks whether the reference
amino acid in the mutation position is matched with the amino acid in the corresponding
protein sequence. The distance filtering refers to the co-occurrence of the mutation, the
protein name, and the organism type in the text. The pairs with the shortest distance (word
counts) are considered as relevant. One limitation of MuteXt is that it is only trained to
retrieve mutations for GPCR and NR protein superfamilies.
MEMA, proposed by Rebholz et al. [82], is another regular expression (RegExp) based
mutation extraction tool that was only applied to the Medline abstracts. The proposed
method has three main steps: i) gene name identification, ii) mutation identification and
iii) disambiguation module. MEMA uses regular expression patterns for both gene and
mutation identification. For gene identification, the method simply searches for any gene
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name that matches with the list of genes obtained from the Human Genome Organization
(HUGO) gene database [79]. A set of 30 different patterns is used for the mutation identification. These include Arg506 to Gln, Ile15 to Thr15, 1166 A/C, C282Y, etc. Then, for
each identified mutation, the method follows a set of certain rules in order to identify the
corresponding gene:
1. If there is only one gene mentioned in the abstract, that gene would be considered
as the corresponding gene.
2. If the abstract contains multiple genes, the corresponding gene would be the one
mentioned in the same sentence as the mutation.
3. If there is more than one gene in the same sentence as the mutation, then the closest
mentioned gene (word counts) to the mutation would be considered as the corresponding gene.
On a sample of 100 abstracts, MEMA achieves 67% recall, and 96% precision rate on the
mutation extraction, and 35% recall, and precision of 93% on the mutation–gene pairs
identification.
Erdogmus et al. [32] proposed MuGeX (Mutation Gene eXtractor) for mutation identification from the Medline abstracts. MuGeX uses a set of 20 different patterns for mutation
extraction such as G12D, Gly-12-Asp, Gly12 to Asp, Substitution of Glycine for Aspartic Acid
at position 12, etc. On a set 231 Medline abstracts the MuGeX mutation detection method
achieves 85.9% and 95.9% recall and precision, respectively. For the mutation–gene pairs
identification, the estimated recall, and precision is 91.3% and 88.9%, respectively. One
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drawback of this method is its inability to identify correct mutation-gene pairs when multiple mutations and genes mentioned in the text.
MutationFinder is another mutation extraction tool proposed by Caporaso et al. [23]
in 2007. The proposed method uses a modified version of the regular expression method
proposed by Erdogmus et al. [32]. These modifications include the following six new rules:
• The numeric position of the one-letter abbreviations mutation format should be
greater than a certain number.
• The one-letter allele of the mutation should be presented in the upper-case format.
• The reference and alternative alleles should not be the same.
• Unlike MuteXt [49], the proposed method is able to identify mutations with the nonalphanumeric characters as well.
• MutationFinder is also able to identify mutations described in the human natural
language in addition to the abbreviated formatted mutations (e.g. Substitution of
Glycine for Aspartic Acid at position 12).
• The regular expression patterns are applied to each sentence separately.
Overall, MutationFinder had better performance (both recall and precision) compared to
MuteXt [49].
Lee et al. [67] proposed Mutation Graph Bigram (Mutation GraB) method for extracting
point mutations from biomedical literature. Similar to the previous methods in this category, mutations and gene names are identified using the pre-defined regular expression
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patterns. As the next step, the proposed method uses the graph-based bigram traversal
method to associate an identified mutation with a corresponding protein. In particular, for
each mutation entity, the method searches for the corresponding gene using the shortest
path distance algorithm. The identified mutation-protein pairs are then verified based on
the Swiss-Prot [16] database.
In 2010, Doughty et al. [29] introduced EMU, a semi-automated method for mutationgenotype-phenotype identification from biomedical literature. The proposed method follows the same regular expression patterns proposed by Garten et al. [39] for the mutation
identification. EMU uses the HUman Genome Organization (HUGO) gene database [79]
as a dictionary containing the list of human genes to extract any gene names or their synonyms from a text. Same as MuteXt [49], EMU also uses sequence filtering to validate the
extracted mutation-gene pairs.
Singhal et al. [96] implemented a machine-learning-based method to extract and identify the disease-related mutations from biomedical literature. The proposed method uses
tmVar [112] and DNorm [64] to extract mutation and disease entities, respectively. For a
target disease, the proposed method uses the following 6 different features to determine
whether the identified mutation G from an input article is related to the target disease D.
1. The number of times the target disease D is mentioned as the closest (based on word
counts) disease to the identified mutation G.
2. The number of times the target disease D is mentioned in the input article.
3. The number of times the next most frequently mentioned disease other than D is
mentioned in the input article.

16
4. Whether the target disease D and the mutation G are mentioned in the same sentence
in the input article (binary score).
5. The sentiment score of the text between the mutation G and its nearest mention of
the target disease D.
6. The subjectivity of the sentiment score was calculated in step 5.
The authors used two benchmark datasets provided by EMU [29] as the training datasets.
As the next step, they used Weka3.6 tool [43] to build a machine learning classifier based
on the training datasets and the developed features set. The results showed the outperformance of the proposed method compared to EMU [29].
In another work, Singhal et al. [97] proposed an automatic framework for extracting
mutation-genotype-phenotype triplet associations from biomedical literature. The main
steps of the proposed work can be summarized as follows:
1. Disease, gene, and mutation identification from an input article using DNorm [64],
GNormPlus [113], and tmVar [112], respectively.
2. Disease-mutation association identification using their previous proposed method [96].
3. Gene-mutation association identification using PubMed Rank, Bing Rank, and sequence filtering methods. In particular, for an identified gene G and an identified
mutation M, these scores are calculated as follows:
• PubMed Rank: the frequency of appearances of the gene G in the abstract section of the articles that are known to be related to the mutation M.
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• Bing Rank: the frequency of appearances of the gene G in the top 20 Bing search
results when searching for the mutation M.
• Sequence filtering: similar to the validation process proposed by Doughty et
al. [29], the sequence filtering process checks whether the reference amino acid
in the mutation position is matched with the amino acid in the associated gene’s
sequence.

18

CHAPTER 3 PROPOSED METHOD
In this thesis, we propose an automated framework to extract disease-associated variants from the full-length biomedical literature and design a variant-driven gene signature
for a given disease phenotype. The process of extracting variants from a full-length article
is challenging because any chemical formulae, figure numbers, etc. that are represented in
a “character-number-character” format could potentially be a variant [114]. One solution
to address this challenge is to mine only the variant-relevant articles. As the first step, the
proposed framework employs word cloud analysis to identify such articles. The variantgene-disease associations are then extracted from these articles using the entity recognition tools. An evidence-based variant-driven gene signature is then generated based on
the mined triplet information. We use a comprehensive validation procedure to illustrate
the capabilities of the proposed framework. We compare the proposed panels with other
variant-driven gene panels obtained from Clinvar [63], Mastermind [40], and others from
the literature [29, 96], as well as with a panel identified with a classical differentially expressed genes (DEGs) approach. The proposed variant-driven gene signatures are then
validated by showing their abilities to predict the patients’ clinical conditions (healthy vs.
disease) on multiple independent validation datasets.
Figure 1 illustrates the proposed framework that consists of the following four major
modules: (1) obtain the full-length variant-relevant articles; (2) extract all the variant,
gene and disease entities from each input article; (3) identify the variant-gene, and the
variant-disease associations in each input article; (4) design a variant-driven gene panel
for a given phenotype. The detailed descriptions of each step are provided in the following
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sections.

Figure 1: Framework overview. Module (A) obtains all the publicly available full-length
articles from the PubMed Central (PMC) database. Then it uses the word cloud analysis
and generate a weighted list of variant-relevant keywords. The variant-relevant articles
are then selected based on the presence of this list in their full text (section 2.1). Module
(B) uses GNormPlus [113], tmVar 2.0 [114] and DNorm [64] tools to extract the gene,
variant, and disease phenotype entities, respectively (section 2.2). Module (C) extracts
the gene-variant associations from each input article (section 2.3). This module also uses
a set of features to discover the disease-variant associations (section 2.4). Module (D)
generates a panel consists of the variant-gene-disease associations.
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3.1

Variant-relevant input corpus

The input of the proposed framework consists of 3,322,746 full-length articles downloaded from the PMC database in January 2020. The variant indexing procedure from a
full-length article is challenging because any chemical formulae, figure numbers, etc. that
are represented in “Character-Number-Character” format could be identified as a variant [114]. One solution to address this challenge is to mine only the variant-relevant articles. We compare the performances of two different approaches for detecting the variantrelevant articles. The first approach considers only the articles that mention any disease
or gene or any of their synonyms in the title and abstract sections [40]. In the second
approach, we employ the word cloud analysis and generate a weighted list of variantrelevant keywords. In particular, we first generate a weighted list of words (referred to as
variant-relevant keywords) that appear frequently in the full-body text of 10,000 random
articles with at least one mentioned variant (using tmVar 2.0). Subsequently, an article is
considered to be relevant to variants if at least 10% of these keywords appear in the fullbody of the article. We apply both approaches on a new set of 10,000 random full-length
articles. Figure 2 shows the identified variant overlaps and differences between the two
approaches.
The number of papers with at least one mentioned variant overlapped between the
two approaches is 836 and the number of overlapped variants is 5,476. The number of
variants that are only found by the first approach is 284 from 91 papers, in which a manual
validation process revealed that 97% of them are false positive (extracted entity is not a
variant and it is wrongly identified as a variant.). The number of variants that are only

21

Figure 2: Among the 10,000 random articles, the articles with at least one mentioned
mutation are selected (using tmVar 2.0). We compare the performances of two different
approaches for detecting the variant-relevant articles. The first approach identifies articles
that mention any disease or gene or any of their synonym in their titles and abstracts [40].
In the second approach, we only search for the articles that mention the variant-relevant
keywords in their full-body text. The variant-relevant keywords list is a weighted list
of the words that appear frequently in a set of 10,000 random articles with at least one
mentioned variants (using tmVar 2.0). Subsequently, an article is considered to be relevant
to variants if at least 10% of these variant-relevant keywords are appearing in the full-body
text. The number of variants that are found in the articles selected by the first approach and
the second approach is 5,760 and 6,087, respectively. The number of variants identified
by both approaches is 5,476. The number of variants that are only found by the first
approach is 284, of which 97% are false positive (extracted entity is not a variant and it is
wrongly identified as a variant.). The number of variants that are only found by the second
approach is 611, of which only 10% are false positive. These results show that the second
approach which is based on the variant-relevant keywords outperforms the first approach.
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found by the second approach is 611 from 122 papers, in which only 10% of them are
false positive. The manual validation of the extracted variants to listed in Appendix Table
33. These results show that the second approach which is based on the variant-relevant
keywords outperforms the first approach. This leads us to the conclusion that the second
approach performs better in terms of the ability to index the variant-relevant articles. This
approach results in a list of 1,274,775 full-length articles that contain genomic variants.

3.2

Extract the variant, gene and disease entities

We use the publicly available and well-known entity recognition tools to extract the
variant, gene, and disease phenotype from each input article. In particular, we use GNormPlus [113] to identify the appropriate genes. The tmVar 2.0 [114] is the tool we employ for
extracting the variants and normalizing those which are included in dbSNP to their unique
identifiers (dbSNP RSIDs). We use DNorm [64] to identify all the disease phenotypes
mentioned in an article.

3.3

Extract the variant-gene associations

Once a variant is extracted from an input article, we follow the steps provided by Wei et
al. [114] to find the associated gene. Then, we map each retrieved variant-gene pair to
the corresponding genomic coordinates (chromosome number, position, reference and alternative alleles) using the Variant Recoder [50] tool. Variant Recoder provides translation
between the different formats of a variant. This tool supports HGVS annotations as well
as dbSNP, Clinvar [63], and PharmGKB [47]. We eliminate the variant-gene associations
with no matched genomic coordinates (referred to as false positive pairs).
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3.4

Extract the variant-disease associations

We use a set of features to capture the variant-disease associations from an input article
adapted from tmVar [96]. Let C = {V, D1 , D2 , ..., Dk } be a collection of appearances of the
variant V and the closest (based on the word counts) mentioned diseases in an article,
where k is the number of times this variant is mentioned in that article. The disease
association score is calculated for each appearance of variant V and the closest mentioned
disease Di , where 1≤i≤k. This score is the summation of the following set of scores:
• The Same Sentence Occurrence (SSO) is a binary score which is 1 when the variant V
and the disease Di are mentioned in the same sentence and 0 otherwise.
• The Same Paragraph Occurrence (SPO) is a binary score which is 1 when the variant V and the disease Di are mentioned in the same paragraph and 0 otherwise.
• The sentiment score (SS) calculates the polarity sentiment value for the text mentioned between the variant V and the disease Di . We use the R package “sentimentr” [86] for this analysis.
The variant V is considered to be associated with disease Di that has the highest disease
association score.
We also performed an experiment to compare the performance of the proposed scoring method for extracting the variant-disease associations with the simple sentence cooccurrence scoring method. In this experiment, we used two manually curated benchmark
datasets provided by Doughty et al. [29]. These datasets contain variant-disease pairs
extracted from 29 and 129 PubMed articles for prostate cancer and breast cancer, respec-
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Table 7: Comparison of the proposed variant-disease association scoring method with the
baseline approach (Co-occurrence only) on the benchmark datasets. These datasets are
provided by Doughty et al. [29]. The proposed approach performs better compare to the
baseline approach.
Corpus

Evaluation metrics
Precison
Recall
Breact cancer
F1 measure
Precison
Prostate cancer Recall
F1 measure

Proposed method
0.90385
0.85455
0.87850
0.91111
0.85417
0.88172

Baseline method
0.31731
0.30000
0.30841
0.37778
0.35417
0.36559

tively. We used these datasets and reported the standard evaluation metrics (precision,
recall and F1-measure) for the proposed scoring approach compared to the sentence cooccurrence scoring approach. As shown in Table 7, the proposed method outperforms the
baseline method which is only based on the sentence co-occurrence appearance of the
variant-disease pairs. The complete list of mined variant-disease pairs for this experience
is listed in Appendix Table 32.

3.5

Variant-driven gene panel design

In this step, we first generate a variant-gene-disease panel which includes all the associations between the gene, variant, and disease entities extracted from the input corpus
(Module D in Figure 1). This panel includes 18,254 genes with 313,780 variants discovered to be associated with 5,202 unique diseases. For a given disease, we then generate
the variant-driven gene panel which includes all the genes with at least one mentioned
variant discovered to be associated with the given disease.
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3.6

Validation method

In this section, we describe two experiments performed to assess the diagnostic value
of the proposed variant-driven gene panel.
In the first experiment, we use the genes present in the proposed panel to predict the
patients’ clinical condition (healthy vs. disease) from several independent patient cohorts.
The hypothesis is that a better gene panel will yield better classification results. For this
purpose, we use disease gene expression datasets and machine-learning classification techniques. A disease gene expression dataset is a matrix in which the rows represent the measured genes and the columns represent the samples (healthy or disease individual). The
value in each cell is the expression level of a gene in a particular sample. We use crossvalidation method for this analysis. In particular, in each round of sampling, we use one
of the gene expression datasets as the training dataset and we use the rest as the testing
datasets. We use the genes present in the proposed variant-driven gene panel along with
their expression values from the training dataset to build a random forest classifier [20].
Then, we apply the trained classifier on each of the testing datasets in order to predict the
patients’ clinical outcomes. We use the area under the curve (AUC) of the receiver-operator
characteristic (ROC) to assess the performance of the classifier. We repeat this procedure
n times (where n is the number of available gene expression datasets). An average of the
AUCs is calculated over the n rounds of sampling. This procedure is used to compare the
diagnostic quality of the proposed gene panel with the current available variant-relevant
gene panels.
In the second experiment, we assess the relevance of the proposed gene panel to a given
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Figure 3: Validation framework overview. Module (A) identifies all the genes with at least
one variant discovered to be associated with the given disease by the proposed framework.
We refer to this list of genes as the proposed variant-driven gene panel. Module (B) first
analyzes several independent gene expression datasets studying the given phenotype. We
use a cross-validation method. In each round of sampling, we use one of the gene expression datasets as the training dataset and we use the rest as the testing datasets. We use
the expression values of the genes included in the proposed gene panel as the features to
build a classifier. Then, we apply the trained classifier on each of the testing datasets in
order to predict the patients’ clinical outcomes in each testing dataset. We use the area
under the curve (AUC) of the receiver-operator characteristic to assess the performance of
the classifier. We repeat this procedure n times (where n is the number of gene expression
datasets). An average of AUCs is calculated over the n rounds of sampling. This procedure
is used to compare the diagnostic quality of the proposed variant-driven gene panel with
the current available variant-relevant gene panels.
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disease based on the rank of the target pathway when an enrichment pathway analysis is
performed. A “target pathway” refers to the pathway that was created to explain the mechanism of the given disease (e.g. the acute myeloid leukemia KEGG pathway (hsa05221) is
the target pathway for acute myeloid leukemia).
A signaling pathway refers to a graph in which nodes represent genes/proteins, and
edges represent existing interactions between such genes or proteins. In general, the main
goal of the pathway analysis methods is the correct identification of the pathways that are
significantly impacted when comparing two phenotypes (e.g. healthy vs. disease) [30, 58].
Many pathway analysis methods have been proposed [75, 76, 58]. A very recent extensive benchmarking of the existing pathway analysis methods are provided by Nguyen et
al. [77].
In this thesis, we use the enrichment pathway analysis method called over-representation
analysis (ORA) [57]. The goal of this method is to find the pathways that are enriched
within a list of genes. In particular, this method calculates the probability of finding a center number of gene overlaps between the proposed gene panel and the presented genes in
each pathway just by chance. For a pathway P, this probability is calculated as follows:

p-value = 1 −

k-1
X
i=0

M
i



N-M
n-i

N
n


(3.1)

In this equation, N is the total number of genes in the genome that have been annotated, n is the total number of genes in the proposed gene panel, k is the total number
of gene overlaps between the proposed gene panel and the pathway P, and M is the total
number of genes included in the pathway P.
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These probability values are calculated for all pathways. Subsequently, they should be
adjusted for multiple comparisons with an approach such as the false discovery rate correction (FDR) [13, 14]. For each pathway, if the FDR-corrected p-value is less than a certain
threshold (usually less than 0.05), then the pathway is considered to be significantly involved in the experiment. The list of significant pathways is then ranked from the one with
the lowest FDR-corrected p-value (most significant) to the one with the highest p-value
(least significant). For this analysis, we use the R package “clusterProfiler v3.12.0” [120].
The expectation here is that a gene panel that is relevant to the given disease would rank
the target pathway at the very top of the ranked list of pathways. This validation method
was widely adopted by others, such as [5, 51, 69, 71, 75, 76, 77, 91, 102]. We also provide
the top 10 significantly enriched pathways and the references explaining the association
of the respective pathways to the disease case study for each gene panel.
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CHAPTER 4 RESULTS
As representative examples, we present the results for acute myeloid leukemia (AML),
breast cancer, and prostate cancer. The resulted gene panel proposed for each case study
is included in the Appendix. All the gene expression datasets used in this manuscript for
the classification analysis are obtained from GEO [12].
For each disease case study, we also calculate the percentage of the genes in the proposed gene panel that overlap with the genes in each gene expression dataset. We performed the following experiment as a quality check to ensure that the majority of the
genes in the proposed gene panel are contributing to the validation analysis. In order to
do this, we calculated the percentage of the genes in the proposed gene panel that overlap
with the genes in the training dataset as follows:

In this equation, N represents the genes in the proposed gene panel and M represents
the genes in the training gene expression dataset. For each case study, the average of this
percentage across all the gene expression datasets is more than 80% (Tables 8 to 10).
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Table 8: The percentage of the genes in each AML gene panel that overlap with the genes
in each GEO gene expression dataset.
Dataset
GSE15061
GSE17054
GSE34577
GSE35008
GSE37307
GSE42140
GSE9476
GSE982
Average

MAGPEL (proposed)
96.94
96.51
97.38
92.58
90.39
96.51
90.39
90.39
93.88

Mastermind
97.44
97.12
98.4
95.53
95.21
97.12
95.21
95.21
96.40

Clinvar [63]
88.68
88.68
88.68
86.79
79.25
88.68
79.25
79.25
84.90

Singhal et al. [97]
90.24
90.24
90.24
87.8
84.15
90.24
84.15
84.15
87.65

Table 9: The percentage of the genes in each prostate cancer gene panel that overlap with
the genes in each GEO gene expression dataset.
Dataset
GSE12348
GSE17906
GSE17951
GSE32448
GSE46602
GSE55945
GSE68882
GSE6956
GSE70768
Average

MAGPEL (proposed)
86.28
97.18
97.18
97.18
97.18
97.18
75.56
86.28
98.31
92.48

EMU [29]
100.00
100.00
100.00
100.00
100.00
100.00
82.35
100.00
100.00
98.04

Clinvar [63]
68.01
89.08
89.08
89.08
89.08
89.08
50.00
68.01
94.44
80.65

Singhal et al. [97]
85.87
94.35
94.35
94.35
94.35
94.35
72.44
85.87
94.35
90.03

Table 10: The percentage of the genes in each breast cancer gene panel that overlap with
the genes in each GEO gene expression dataset.
Dataset
GSE10780
GSE10810
GSE20086
GSE29431
GSE36295
GSE42568
GSE54002
GSE61304
GSE86374
GSE8977
Average

MAGPEL (proposed)
97.66
75.05
97.66
97.66
94.74
97.66
97.66
97.66
94.74
92.01
94.25

EMU [29]
100.00
72.73
100.00
100.00
95.45
100.00
100.00
100.00
95.45
95.45
95.91

Clinvar [63]
85.64
50.21
85.64
85.64
85.47
85.64
85.64
85.64
85.47
73.83
80.88

Singhal et al. [97]
86.90
61.90
86.90
86.90
85.69
86.90
86.90
86.90
85.69
79.44
83.41
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4.1

Acute myeloid leukemia

First, we extract all the genes with at least one mentioned variant discovered to be associated with AML by the proposed framework (Table 29). The top 10 genes that have the
highest number of variants are TP53, FLT3, KIT, DNMT3A, IDH1, COX8A, RUNX1, TYMS,
NPM1, and SLC29A1. These genes play significant roles in the underlying mechanisms of
AML. For instance, Kadia et al. [56] demonstrated that AML patients with TP53 alterations
have a lower response rate to intensive chemotherapy and therefore have an inferior survival rate. FLT3 and C-KIT are known to be associated with poor AML prognosis discovered
by Pratz et al. [80] and Yang et al. [117], respectively. Ley et al. [68] investigated the role
of DNMT3A and found that there is a direct link between the presence of mutations in this
gene and the intermediate risk of AML. Chaturvedi et al. [27] also reported the therapeutic role of mutant IDH1 in AML. Gaidzik et al. [37] have shown that therapy-resistance
and inferior outcomes are the main genetic characteristics of AML patients with RUNX1
mutations. The presence of mutations in TYMS and NPM1 is also discovered in AML patients [38, 70]. SLC29A1 mutations are found to be associated with poor therapy outcome
in AML patients [59].
We assess the utility of the proposed gene panel on independent gene expression
datasets studying AML obtained from GEO [12]. Dataset summaries are described in Table 11.
The other variant-driven gene panels which are available for AML are obtained from
Clinvar [63], Mastermind [40], and the panel proposed by Singhal et al. [97] Clinvar
is a repository for mutations and their associated disease phenotypes which are man-
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Table 11: Summary of the datasets used for the AML case study.
#Disease
samples
202

#Control
samples
69

Dysregulated gene expression networks in human acute
myelogenous leukemia stem cells
pediatric AML and normal bone marrow

9

4

54

4

Routine use of microarray-based gene expression profiling to
identify patients with low cytogenetic risk acute myeloid
leukemia
Expression data from human hematopoietic stem and progenitor
compartments from patients with acute myeloid leukemia with
normal karyotype and healthy controls
Aberrant expressed genes in AML

21

8

12

16

30

19

Gene expression in signaling subsets of AML blasts induced by
G-CSF
Abnormal expression changes in AML
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7

26

38

Gene Expression-Based High Throughput Screening: HL-60 Cell
Treatment with Candidate Compounds

9

6

Dataset

Title

GSE15061

Gene array prediction of AML transformation in MDS

GSE17054
GSE2191
GSE34577
GSE35008
GSE37307
GSE42140
GSE9476
GSE982

ually curated from the biomedical literature. The Mastermind search engine provides
literature-based variant-genotype-phenotype association information. We also include the
results when using only the differentially expressed genes (FDR-corrected p-value<0.05
and | log2 (fold change)|>=1.5) as a gene panel. Figure 4 illustrates the performance comparison of these gene panels. The results show that the classification based on the proposed
gene panel achieves the best result (the highest median AUC value) and outperforms the
classification based on all the other published panels.
The results for the pathway enrichment analysis are summarized in Table 12. The
proposed gene panel has better performance than the other available panels and ranked
the AML target pathway as the top-ranked pathway. The top 10 significantly enriched
pathways and the references explaining the association of the respective pathways to AML
for each gene panel are summarized in (Tables 13 to 16).

33

Figure 4: The diagnostic performances of the random forest classifier based on five different gene panels. In this figure, the proposed panel (blue panel) performs better than
the ones obtained from Clinvar (red panel), Mastermind [40] (purple panel), the panel
proposed by Singhal et al. [97] (green panel), and the differentially expressed genes (FDRcorrected p-value<0.05 and | log2 (fold change)|>=1.5) (DEGs) (olive-tone panel) in terms
of the ability to distinguish between healthy volunteer and the AML patients. In this figure, the black dot inside each box plot represents the mean AUC value and the dashed line
represents the highest median AUC value.

Table 12: The results of the pathway enrichment analysis based on four different gene
panels for AML. The comparison is based on the rank of the acute myeloid leukemia KEGG
pathway (hsa05221). The proposed panel performs better in terms of the ability to highly
rank the target pathway.
Panel
Number of genes Rank of target pathway
MAGPEL (proposed) 229
1
Clinvar [63]
53
2
Singhal et al. [97]
76
3
Mastermind [40]
313
9

p-value (FDR)
1.57E-15
8.36E-07
1.62E-14
5.50E-26
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Table 13: The top 10 significantly enriched pathways identified by the enrichment pathway
analysis based on the proposed gene panel (MAGPEL) for AML case study. Rows with green
background indicate the target pathway for AML. Rows with blue background indicate
pathways for which we found indication of their association to AML.
Rank
1
2
3
4
5
6
7
8
9
10

Pathway name
Acute myeloid leukemia
PI3K-Akt signaling pathway [1, 61]
Transcriptional misregulation in cancer [88]
Prostate cancer
ErbB signaling pathway [109]
Chronic myeloid leukemia [90]
PD-L1 expression and PD-1 checkpoint pathway in cancer
JAK-STAT signaling pathway [33]
Hepatitis B
EGFR tyrosine kinase inhibitor resistance

p-value (FDR)
1.57E-15
2.42E-11
1.44E-10
1.44E-10
1.44E-10
2.26E-10
2.26E-10
1.26E-09
1.26E-09
3.18E-09

Table 14: The top 10 significantly enriched pathways identified by the enrichment pathway analysis based on the Clinvar [63] gene panel for AML case study. Rows with green
background indicate the target pathway for AML. Rows with blue background indicate
pathways for which we found indication of their association to AML.
Rank
1
2
3
4
5
6
7
8
9
10

Pathway name
PI3K-Akt signaling pathway [1]
Acute myeloid leukemia
Central carbon metabolism in cancer [18]
PD-L1 expression and PD-1 checkpoint pathway in cancer
Thyroid cancer
Bladder cancer
Chronic myeloid leukemia [90]
EGFR tyrosine kinase inhibitor resistance
Endometrial cancer
Non-small cell lung cancer

p-value (FDR)
2.53E-07
8.36E-07
8.36E-07
3.76E-06
1.54E-05
1.89E-05
1.89E-05
2.08E-05
8.42E-05
0.00014
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Table 15: The top 10 significantly enriched pathways identified by the enrichment pathway
analysis based on the Singhal et al. [97] gene panel for AML case study. Rows with green
background indicate the target pathway for AML. Rows with blue background indicate
pathways for which we found indication of their association to AML.
Rank
1
2
3
4
5
6
7
8
9
10

Pathway name
JAK-STAT signaling pathway [33]
Chronic myeloid leukemia [90]
Acute myeloid leukemia
Human T-cell leukemia virus 1 infection
Transcriptional misregulation in cancer [88]
Hepatitis B
PI3K-Akt signaling pathway [1]
Non-small cell lung cancer
Central carbon metabolism in cancer [18]
Pancreatic cancer

p-value (FDR)
2.13E-17
4.70E-15
1.62E-14
1.44E-10
1.53E-09
2.39E-09
2.39E-09
4.48E-09
6.29E-09
1.51E-08

Table 16: The top 10 significantly enriched pathways identified by the enrichment pathway
analysis based on the Mastermind [40] gene panel for AML case study. Rows with green
background indicate the target pathway for AML. Rows with blue background indicate
pathways for which we found indication of their association to AML.
Rank
1
2
3
4
5
6
7
8
9
10

Pathway name
Hematopoietic cell lineage
JAK-STAT signaling pathway [33]
PI3K-Akt signaling pathway [1]
Transcriptional misregulation in cancer[88]
Hepatitis B
Human T-cell leukemia virus 1 infection
Epstein-Barr virus infection
Kaposi sarcoma-associated herpesvirus infection
Acute myeloid leukemia
Prostate cancer

p-value (FDR)
6.98E-37
1.11E-34
6.78E-34
1.97E-30
2.60E-30
8.14E-30
7.66E-29
1.53E-27
5.50E-26
6.83E-26
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4.2

Prostate cancer

In this case study, we discover 532 genes with variants associated with prostate cancer (Table 30). The proposed prostate cancer variant-driven gene panel contains several
genes known to be involved in prostate cancer development and progression. For instance,
the androgen receptor (AR) plays important role in prostate cancer cell proliferation as
demonstrated by Balk et al. [10] The mutated BRCA2, TP53, KLK3, and RNASEL genes are
directly associated with the risk of developing prostate cancer [108, 31, 60, 26]. SPOP is
the most frequent mutated gene in primary prostate cancer [11, 19].
The gene expression dataset summaries are described in the Table 17.
Table 17: Summary of the datasets used for prostate cancer case study.
Dataset

Title

GSE12348

Prostate cancer cell lines and normal prostate epithelial and
stromal cells in primary culture
Gene expression down-regulation in prostate tumor-associated
stromal cells involves organ-specific genes
Gene expression analysis of prostate cancer samples using
Affymetrix U133Plus2 array
CPDR tumor-benign 80 genechip dataset
Expression data from prostate cancer and benign prostate glands
Gene expression profiling of prostate benign and malignant
tissue
Comprehensive gene expression analysis of prostate cancer
reveals distinct transcriptional programs associated with
metastatic disease
Tumor immunobiological differences in prostate cancer between
african-american and european-american men
Prostate cancer stratification using molecular profiles

GSE17906
GSE17951
GSE32448
GSE46602
GSE55945
GSE68882
GSE6956
GSE70768

#Disease
samples
6

#Control
samples
3

10

10

68

13

40
36
13

40
14
8

23

3

69

18

125

74

The classification results also demonstrate that the proposed gene panel outperforms
the other available gene panels [63, 97, 29] in terms of the ability to predict the patients’
clinical outcome on several independent validation cohorts (Figure 5).
The results for the pathway enrichment analysis are summarized in Table 18. The
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Figure 5: The diagnostic performances of the random forest classifier based on five different gene panels. In this figure, the proposed panel (blue panel) performs better than
the ones obtained from Clinvar (red panel), the panels proposed by Singhal et al. [97]
(purple panel), EMU [29] (green panel), and also the differentially expressed genes (FDRcorrected p-value<0.05 and | log2 (fold change)|>=1.5) (DEGs) (olive-tone panel) in terms
of the ability to distinguish between healthy volunteer and the breast cancer patients. In
this figure, the black dot inside each box plot represents the mean AUC value and the
dashed line represents the highest median AUC value.
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top 10 significantly enriched pathways and the references explaining the association of
the respective pathways to prostate cancer for each gene panel are also summarized in
(Tables 19 to 22).
Table 18: The results of the enrichment pathway analysis based on different gene panels
obtained for prostate cancer. The comparison is based on the rank of the prostate cancer
KEGG pathway (hsa05215).
Panel
Number of genes Rank of target pathway
MAGPEL (Proposed) 532
1
Clinvar [63]
525
7
Singhal et al. [97]
280
1
EMU [29]
17
2

p-value (FDR)
5.49E-28
5.10E-05
8.12E-12
5.83E-07

Table 19: The top 10 significantly enriched pathways identified by the enrichment pathway analysis based on the proposed gene panel (MAGPEL) for prostate cancer case study.
Rows with green background indicate the target pathway for prostate cancer. Rows with
blue background indicate pathways for which we found indication of their association to
prostate cancer.
Rank
1
2
3
4
5
6
7
8
9
10

Pathway name
Prostate cancer
FoxO signaling pathway [92]
Endocrine resistance
Colorectal cancer
Pancreatic cancer
PI3K-Akt signaling pathway [94]
AGE-RAGE signaling pathway in diabetic complications
Endometrial cancer
Chronic myeloid leukemia
Bladder cancer

p-value (FDR)
5.49E-28
3.13E-25
2.29E-21
2.29E-21
3.54E-21
2.35E-20
4.05E-19
3.96E-18
6.04E-18
1.51E-17
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Table 20: The top 10 significantly enriched pathways identified by the enrichment pathway analysis based on the Clinvar [63] for prostate cancer case study. Rows with green
background indicate the target pathway for prostate cancer. Rows with blue background
indicate pathways for which we found indication of their association to prostate cancer.

Rank
1
2
3
4
5
6
7
8
9
10

Pathway name
p-value (FDR)
Pancreatic cancer
1.93E-06
Endometrial cancer
1.96E-06
Melanoma
1.69E-05
Endocrine resistance
1.69E-05
Breast cancer
2.71E-05
Non-small cell lung cancer 2.74E-05
Prostate cancer
5.10E-05
Colorectal cancer
6.29E-05
Glioma
7.57E-05
Bladder cancer
8.38E-05

Table 21: The top 10 significantly enriched pathways identified by the enrichment pathway analysis based on the EMU [29] for prostate cancer case study. Rows with green
background indicate the target pathway for prostate cancer. Rows with blue background
indicate pathways for which we found indication of their association to prostate cancer.

Rank
1
2
3
4
5
6
7
8
9
10

Pathway name
p-value (FDR)
Endometrial cancer
4.96E-08
Prostate cancer
5.83E-07
Gastric cancer
5.13E-06
Colorectal cancer
8.28E-06
Platinum drug resistance 0.00015237
Hepatocellular carcinoma 0.00015268
Thyroid cancer
0.00054001
Bladder cancer
0.00064535
Breast cancer
0.00133837
Hepatitis C
0.00147899

Table 22: The top 10 significantly enriched pathways identified by the enrichment pathway
analysis based on the Singhal et al. [97]for prostate cancer case study. Rows with green
background indicate the target pathway for prostate cancer. Rows with blue background
indicate pathways for which we found indication of their association to prostate cancer.
Rank
1
2
3
4
5
6
7
8
9
10

Pathway name
Prostate cancer
Hepatitis B
Platinum drug resistance
Bladder cancer
FoxO signaling pathway [92]
Steroid hormone biosynthesis
Pancreatic cancer
Transcriptional misregulation in cancer
PI3K-Akt signaling pathway [94]
Endometrial cancer

p-value (FDR)
8.12E-12
1.82E-08
2.85E-07
2.85E-07
3.12E-07
1.66E-06
1.95E-06
1.95E-06
3.08E-06
5.58E-06
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4.3

Breast cancer

The resulted panel for breast cancer includes 513 genes. This panel contains several
genes that are known to play crucial roles in the underlying mechanisms of breast cancer.
For instance, BRCA1, BRCA2, TP53, ESR1, PIK3CA, ERBB2, and PALB2 are among the
genes with a high number of variants associated to breast cancer. The mutations in BRCA1,
BRCA2, and TP53 are well-known to be associated with a high breast cancer risk [35, 111].
ESR1 mutations are involved in hormone-resistant metastatic breast cancer [87, 107, 48,
36, 54]. PIK3CA is an oncogene in breast cancer [22, 7, 98, 52] and ERBB2 is shown to be
up-regulated in several breast tumors [45, 110, 116, 84]. PALB2 is also reported as one of
the breast cancer susceptibility genes [81, 6, 106, 121].
The gene expression dataset summaries are described in Table 23.
Table 23: Summary of the datasets used for breast cancer case study.
Dataset

Title

GSE10780

Proliferative genes dominate malignancy-risk gene panel in
histologically-normal breast tissue
Gene expression panels in breast cancer distinguish phenotype
charact., histological subtypes, and tumor invasivness
Heterogeneity of gene expression in stromal fibroblasts of human
breast carcinomas and normal breast
Identifying breast cancer biomarkers
Transcriptomic analysis of breast cancer
Breast cancer gene expression analysis
Gene expression profiling of LCM captured breast cancer cells
Novel bio-marker discovery for stratification and prognosis of
breast cancer patients
Analysis of somatic DNA copy number alterations and frequency
of breast cancer intrinsic subtypes from Mexican women
Bone-marrow-derived mesenchymal stem cells promote breast
cancer metastasis

GSE10810
GSE20086
GSE29431
GSE36295
GSE42568
GSE54002
GSE61304
GSE86374
GSE8977

#Disease
samples
42

#Control
samples
143

31

27

6

6

25
45
67
417
56

12
5
17
16
4

50

36

7

15

We compare our panels with several other previously proposed variant-driven breast
cancer gene panels as follows: i) Clinvar [63], ii) Singhal et al. [97], iii) Doughty et al. [29]
and iv) the classical DEGs. The classification results demonstrate that the gene panel
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proposed here performs better than the other gene panels in terms of the ability to predict
the patients’ clinical outcome on several independent validation datasets (Figure 6).

Figure 6: The diagnostic performances of the random forest classifier based on five different gene panels. In this figure, the proposed panel (blue panel) performs better than the
ones obtained from Clinvar (red panel), the panels proposed by Singhal et al. [97] (purple
panel) and Doughty et al. [29] (green panel), and also the differentially expressed genes
(FDR-corrected p-value<0.05 and | log2 (fold change)|>=1.5) (DEGs) (olive-tone panel) in
terms of the ability to distinguish between healthy volunteer and the breast cancer patients. In this figure, the black dot inside each box plot represents the mean AUC value
and the dashed line represents the highest median AUC value.

The results for the pathway enrichment analysis are summarized in Table 24. The top
10 significantly enriched pathways and the references explaining the association of the
respective pathways to breast cancer for each gene panel are summarized in (Tables 25
to 28).
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Table 24: The results of the enrichment pathway analysis based on different gene panels
obtained for breast cancer. The comparison is based on the rank of the breast cancer KEGG
pathway (hsa05224).
Panel
Number of genes Rank of target pathway
MAGPEL (Proposed) 513
15
Clinvar [63]
445
22
Singhal et al. [97]
100
152
EMU [29]
44
6

p-value (FDR)
5.21E-16
1.45E-01
4.96E-15
1.46E-09

Table 25: The top 10 significantly enriched pathways identified by the enrichment pathway
analysis based on the proposed gene panel (MAGPEL) for breast cancer case study. Rows
with green background indicate the target pathway for breast cancer. Rows with blue
background indicate pathways for which we found indication of their association to breast
cancer.
Rank
1
2
3
4
5
6
7
8
9
10

Pathway name
Proteoglycans in cancer
Pancreatic cancer
ErbB signaling pathway [46]
Colorectal cancer
Endocrine resistance
Chronic myeloid leukemia
Endometrial cancer
Hepatitis B
Prostate cancer
EGFR tyrosine kinase inhibitor resistance

p-value (FDR)
2.54E-27
2.41E-24
1.14E-23
1.41E-23
2.51E-21
3.95E-21
1.67E-20
1.46E-18
1.57E-18
1.94E-18

Table 26: The top 10 significantly enriched pathways identified by the enrichment pathway
analysis based on the Clinvar [63] gene panel for breast cancer case study. Rows with green
background indicate the target pathway for breast cancer. Rows with blue background
indicate pathways for which we found indication of their association to breast cancer.
Rank
1
2
3
4
5
6
7
8
9
10

Pathway name
Herpes simplex virus 1 infection
Taste transduction
Natural killer cell mediated cytotoxicity [4]
Antigen processing and presentation
Fanconi anemia pathway
B cell receptor signaling pathway
Human papillomavirus infection
Graft-versus-host disease
Pancreatic secretion
Aldosterone-regulated sodium reabsorption

p-value (FDR)
2.67E-21
0.000787
0.000787
0.00196105
0.00196105
0.00317
0.00691236
0.00691236
0.02699356
0.02707948
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Table 27: The top 10 significantly enriched pathways identified by the enrichment pathway
analysis based on the EMU [29] gene panel for breast cancer case study. Rows with green
background indicate the target pathway for breast cancer. Rows with blue background
indicate pathways for which we found indication of their association to breast cancer.
Rank
1
2
3
4
5
6
7
8
9
10

Pathway name
Prostate cancer
Endometrial cancer
Homologous recombination [21]
Melanoma
Platinum drug resistance
Breast cancer
Hepatocellular carcinoma
Bladder cancer
Gastric cancer
Glioma

p-value (FDR)
8.68E-11
3.85E-10
6.27E-10
1.33E-09
1.33E-09
1.46E-09
5.35E-09
1.38E-08
2.44E-08
2.74E-08

Table 28: The top 10 significantly enriched pathways identified by the enrichment pathway
analysis based on the Singhal et al. [97] gene panel for breast cancer case study. Rows
with green background indicate the target pathway for breast cancer. Rows with blue
background indicate pathways for which we found indication of their association to breast
cancer.
Rank Pathway name
p-value (FDR)
1
Proteoglycans in cancer
1.01E-20
2
Colorectal cancer
2.49E-20
3
Pancreatic cancer
4.76E-20
4
Prostate cancer
7.23E-20
5
Chronic myeloid leukemia
4.46E-19
6
Gastric cancer
3.30E-18
7
ErbB signaling pathway [46] 1.22E-17
8
Hepatocellular carcinoma
2.89E-17
9
Endometrial cancer
6.50E-17
10
Endocrine resistance
6.76E-17
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CHAPTER 5 DISCUSSION
We investigate the novelty of our identified genes by checking their overlap with other
available variant-driven gene panels for AML (Figure 7). Although 58% of the proposed
genes are not included in the other panels, the classification and pathway analysis based on
these genes achieve the best results. The gene differences between the proposed panel and
Clinvar could arise from the fact that Clinvar is a manually curated database. In principle,
manual curation is expected to yield very accurate but possibly incomplete annotations,
which is consistent with the smaller number of genes included in the Clinvar panel. The
consideration of only the title and abstract of the articles for extracting the variants by
Singhal et al. [97], could be the reason for the gene differences between these two panels.
The corresponding figures for prostate cancer and breast cancer are shown in Figures 8
and Figures 9, respectively.
We also investigate the percentage of the identified AML-related variants which are
mentioned in the title and abstract sections of the articles and compared them with those
that are mentioned in the full body of the articles but not in the title and the abstract.
Figure 10 visualizes the variant overlaps and differences between these sections. As the
figure shows, about 89% of the variants mentioned in an article do not appear in the
title and the abstract section, which emphasizes the need to analyze the entire text of the
articles. This represents a significant limitation of the existing methods that use only the
title and abstract sections of an article. The Venn diagrams for prostate cancer and breast
cancer are shown in Figures 11, 12, respectively.
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Figure 7: An overview of the gene overlaps and differences between the variant-driven
gene panels. The proposed gene panel (MAGPEL) consists of 229 genes. The AML-related
gene panel obtained from Clinvar and Mastermind includes 53 and 313 genes, respectively,
and the one proposed by Singhal et al. [97] includes 76 genes.

Figure 8: An overview of the gene overlaps and differences between the variant-driven
gene panels for prostate cancer. The proposed gene panel (MAGPEL) consists of 532 genes.
The prostate cancer-related gene panel obtained from Clinvar and EMU includes 525 and
17 genes, respectively, and the one proposed by Singhal et al. [97] includes 280 genes.
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Figure 9: An overview of the gene overlaps and differences between the variant-driven
gene panels for breast cancer. The proposed gene panel (MAGPEL) consists of 513 genes.
The breast cancer-related gene panel obtained from Clinvar and EMU includes 2,354 and
44 genes, respectively, and the one proposed by Singhal et al. [97] includes 445 genes.

Figure 10: An overview of the overlap and differences between the variants mentioned in
the title and abstract sections of the articles (green) and those that appear in the full body
of the articles but not in the title and abstract section (gold) in AML case study.
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Figure 11: An overview of the overlap and differences between the variants mentioned in
the title and abstract sections of the articles (green) and those that appear in the full body
of the articles but not in the title and abstract section (gold) in prostate cancer case study.

Figure 12: An overview of the overlap and differences between the variants mentioned in
the title and abstract sections of the articles (green) and those that appear in the full body
of the articles but not in the title and abstract section (gold) in breast cancer case study.
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CHAPTER 6 CONCLUSION
6.1

Summary of contributions

The number of published articles describing the disease-related variants had a dramatic
rise because of the recent advance sequencing technologies. This highlights the pressing
need for the development of automated tools that are able to extract the variant-disease
associations from literature. The manual extraction of this type of information from the
biomedical literature takes an enormous amount of time and effort. Several automatic
variant indexing tools have been developed to assist this manual curation. Correctly retrieving the disease-associated variants from biomedical texts remains a challenge mainly
because of the complexity of the natural language processing and inconsistent use of standard recommendations for variant description.
Here, we present an automated framework to design an evidence-based variant-driven
gene signature for a given disease phenotype. The identification of the variant-relevant
articles using the word cloud analysis and the consideration of the full-length articles are
the main contributions of the proposed framework. We illustrate the diagnostic value
of the proposed gene signatures in capturing the mechanism involved in acute myeloid
leukemia (AML), breast cancer, and prostate cancer using 29 independent gene expression
datasets containing a total of 2,203 patients. We compare our signatures with several other
available gene signatures as follows: i) Clinvar [63], ii) Mastermind [40], iii) Singhal et
al. [97], iv) Doughty et al. [29] and v) the classical differentially expressed genes. The
results show that the signatures obtained by the proposed framework yield better results
than the other signatures currently available for these phenotypes.
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We believe the proposed framework has significant advantages since it could be used
to identify the gene biomarkers that describe the key biological phenomena for a given
disease. The proposed framework is expected to be of interest to researchers from the
computational biology and machine learning community.

6.2

Future work

In this thesis, we proposed an automated framework to extract the variant-gene-disease
associations from biomedical literature. Studies have been shown the role of genomic mutations in improving the patient survival rate, personalizing medicine, and also reducing
the risks of different therapies and drug responses [72]. However, the same as variants,
this information is also buried in the scientific literature. Future work involves the identification and extraction of associations between genomic variants and drug responses from
literature. For this purpose, first, we will use tmChem [65] to extract any chemical and
drug names from biomedical text. Then, we will use a set of features to identify the associations between the mentioned mutations and drug responses. Similar to the method
proposed by Mahmood et al. [72], our main interest is to capture the association between
mutation existence and the drug responses and the treatment outcome. We will use a gold
standard benchmark dataset named BRONCO [66] to validate the extracted variant-drug
response associations. Lee et al. [66] generated BRONCO which contains associations
between variant, gene, disease, drug, and cell line entities extracted from 108 full-text
biomedical articles. We will use the BRONCO dataset and will report the standard evaluation metrics (precision, recall, and F1 score) for the proposed framework.
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APPENDIX A
Table 29: The list of variant-driven genes obtained by the proposed framework for AML.
FLT3
PSMD5
IDH2
DNMT3A
LYZL4
CD274
NUP98
MYC
FOSL2
PPP2R2A
MTOR
IPO9
EGFR
RLF
SMC1A
CYR61
CYP1B1
IL17A
ERCC2
ASPG
SERPINA1
MPO
SLC24A3
ZHX2
IL17F
MAP4

ATM
GFI1
FBXW7
LUC7L2
MPL
CDCA7L
CBFB
MAPK8
INO80B
LYST
CD33
NT5C2
CYP2C19
GRM1
NCOR1
FYN
MAF
UNG
MARCO
NQO1
BRCA2
SETBP1
FKBP5
BRCA1
PDE9A
ESR1

STAT3
CD8A
SKI
ZNF672
LYPLA1
PRPF4B
CD34
TNFRSF11A
MTHFR
NCR2
PLXNB1
CBL
ADAR
LRP11
MALT1
ABCB1
ABCG2
HDAC9
WRN
FASLG
MECP2
XRCC1
MYBPC3
PDCD1
KLF1
LSD1

CD38
SAMHD1
SPI1
GH1
EZH2
TRIB1
GLI1
PIP4K2A
PPP2R1A
FTO
STAT1
KMT2A
APOBEC3A
CREB1
SF3B1
BCOR
HLA-G
CTNNB1
NAPRT
HAMP
CYP2E1
CYP3A4
CYP1A1
SLU7
DNMT3B

GSK3A
U2AF1
CSF3R
ARHGAP35
KIT
CYP3A5
PDGFRA
PTPN11
ERBB2
ALKBH1
KMT2B
ZBTB7A
RUNX1T1
MAPT
TYK2
SMYD2
ARID5B
JAK3
IL10
CXCR4
CDA
REST
TLR4
SRSF2
RAD52

GSK3B
BCR
CEBPA
MYBPC2
TP53
EIF4EBP1
ABL1
CDK6
CALR
PIK3CA
SHH
MDM2
TERT
TAPBPL
SETD2
TYMS
SLC29A1
EIF4E
CRBN
RAD51
CYP4F2
TOP3A
HSPD1
CREBBP
PIM1

STAT5B
ERG
IDH1
RPS10
JAK2
MYB
RUNX1
PGK2
ASXL1
EDNRB
EIF4B
WT1
ELANE
PTPA
PML
PTMS
TET2
GATA1
FOXP3
FANCB
MAP2K7 NUP62
DDX41
HDAC1
IL3
FOS
CDKN1B ETV6
ASXL3
RUNX3
COX8A
FSTL4
HLA-C
HPSE
NR3C1
CTD
GSTP1
NAT2
PPP2R1B RMI1
CXCR6
XPC
CXXC5
ZNF763
DCK
FANCA
CRP
BCL2
FPGS
DHX15

RPS6KB1
NPM1
HCFC1
TNS3
MYD88
EEF1A2
GATA2
ZNF221
ZNF274
KIR2DL4
RUNX2
NRAS
SMARCA5
NOD2
HHEX
KRAS
MIR204
HOXA9
HFE
ANKRD26
POU1F1
CYTB
SH2B3
ARIH2
ALK
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Table 30: The list of variant-driven genes obtained by the proposed framework for prostate
cancer.
SNCA
MYC
AKT1
CYR61
ARF6
BCHE
CDK5
RNF19A
IRS1
KIT
ACTR1B
SMAD4
TGFBR2
FAM83G
PRKAA2
LIN28B
USP39
NSD2
ERG
WDR77
ABI1
F2RL1
CTCF
PIK3CA
TNFSF10
DNAH8
PPP6R2
ETS1
BRAF
RHOD
MID1
ROCK2
RNASEH2A
APOE
PAK6
RIT2
SDK1
GPX1
HSD17B4
ERCC1
SHBG
PKD1L3
OAS2
BCL11A
IL10
NOD2
MC4R
PPARG
ABCC4
CCL5
GP6
NSD1
CX3CR1
ZBTB10
IL21
PCSK9
ALDH2
SETD7
CBR1

STAT3
MAPKAPK2
TRPV6
SQSTM1
SYTL1
RNASEL
BDNF
ATM
KLK4
PKN1
RNF41
KMT2D
HUWE1
USP44
MAGEA11
GZMM
GSTK1
USF2
RASSF1
MFSD2A
KEAP1
RAB11A
EWSR1
PIK3R1
CASP8
BRIP1
TK1
USP2
KDM4C
NFKB1
PDE4D
SH3KBP1
HSD3B1
TRAM1
FASN
ABCB4
LILRA3
EPHX1
HTR3B
DUT
EPHB2
GCKR
CCHCR1
NPHP1
FTO
CASR
TNF
RAD51
SHMT1
FGF10
MMP2
BAG6
CDON
AHR
SOD2
BIK
PRDM9
MARCHF8
HMGA2

AR
YAP1
CDKN1B
PTEN
MDM2
RALA
CHUK
RPS6KB1
PARP1
PLK1
USP7
EEF1A2
RAB8A
TBC1D10A LCN2
FOXA1
ADORA2A LPAR2
ABCB1
C3
TRIM27
PRKDC
ATR
ERCC3
KLK14
BUB1B
KRAS
HOTAIR
KLK2
CNOT1
ELAC2
AKT3
PSMD4
NOTCH4
SUMO4
SENP2
MYO1C
HIST2H3C CASP3
CHD1
CDC42
SUMO2
HIST2H2AA3 KRT79
PAK2
CD40LG
MAGEC3
EP300
E2F1
HIF1A
FOLH1
GSK3B
C9orf3
ID4
SLC19A1
MRNIP
BAZ2A
CTSA
ATP4A
DAB2IP
TREX2
IL17RA
AGAP2
GHRL
FSD1
IGFBP2
EFNA5
UXT
MLPH
EPHA5
ABL2
TRRAP
ESR1
CD82
SATB2
TSC2
FKBP4
IGF1R
PCSK1
MAP3K8
TARDBP
CDK4
STK11
INTS6
CYP1A1
OTUB1
NCOR1
CXCR4
MAPK1
IL31RA
RPS6KB2
SERPINA1 PRPF31
CCND1
SIAH2
SH3RF1
SNRNP70
CYP17A1
GPRC6A
KRT6A
BTG2
EHMT2
CDKN2A
KMT2C
KMT2A
REPS2
AMPH
SGK1
ALS2CR12
TMPRSS2
APOB
IL10RB
ITGA2
CYP2R1
HNF1B
EPCAM
AXIN2
LINC00673
ORAI1
EFNB2
ABL1
IDH1
CDKAL1
ITGA6
IRX4
TERC
ERCC2
KLF12
LDAH
NFAT5
THADA
DKK3
CYP24A1
CDH1
MGMT
ADIPOQ
PRMT6
GOLPH3L
XRCC1
CCR2
MLH1
MC1R
LIG4
CA4
FOXP4
CYP2E1
IL2
FOXO3
IL10RA
G6PC2
MRTFB
VGLL3
EHBP1
MSH5
POLB
DHODH
P2RX7
FMN1
CYP2D6
HAPLN1
TLR10
GRIK1
CTBP2
TLR4
BCL2
OPRD1
FUT2
PEX14
MMAB
SIX1
ZNF652
JAK2
PEX2
AMZ2
NCOR2
HLA-DRB1 NOL10

PIM1
SH3BP1
PSMD5
CDKN1A
EIF4E
BMPR2
LAMP1
FANCA
BRCA1
CYB5A
ULK1
TP63
DHX15
SENP6
HAT1
HEY1
MCM3
RAB5A
RAD50
SKP2
MED25
CUL3
S100A10
MSH2
GRK3
ATF3
APOBEC3G
NR2E1
HSPA4
DTYMK
DEFB109C
CYP1B1
BGLAP
VDR
NANOG
COX18
MSH6
OAS1
FBN1
IGFBP3
TCF7L2
SORT1
CHEK2
ABCG2
GSTP1
MAPT
NOS3
XPC
TLR5
IL1RN
ERAP1
CCND2
MUC1
COMT
LCT
FANCI
ADIPOR1
NAALADL2
CTDSPL

FOXO1
RAC1
PRL
IFI27
PALB2
TRA
ZFHX3
HDAC2
HDAC1
USP10
TMEM37
PRKD1
PDPK1
ALOX12
CXCL8
MLX
MTOR
WDR35
MSR1
IGF1
HCFC1
SPDEF
IFT81
ELK1
CREB1
CHRM3
CHD4
KRT14
NCOA2
CDK1
FRMD6
PLAT
ACPP
PARD6A
ARF1
TERT
TMEM38B
MSMB
LEPR
PHLPP2
ADH1B
PPFIBP2
AARS2
CCDC78
CYP19A1
POR
TGFB1
KDR
TNFRSF11B
TBX1
XAGE3
LPL
SLCO1B1
WFS1
SRD5A2
NR5A2
RMST
JMJD1C
MYO6

EGFR
PDE8B
STAT5A
UGDH
TP53
HOXB13
KLK3
MLH3
TET1
AMD1
BRCA2
MARK2
EZH2
KLF6
MAP2K1
NCOA3
PCA3
ETV6
SEMA6B
VEGFA
ST8SIA4
NFKBIA
FCF1
ETS2
GAPDH
HRAS
FAT1
INF2
TBP
SS18L1
MAPK8
ERBB3
PSMD9
ANXA2
TNK2
SPTY2D1
JAZF1
SCARB1
IL1B
NAT2
GPRC5B
OCA2
TACSTD2
LRSAM1
EPAS1
CDKN2B-AS1
NQO1
TLR9
COL1A1
PSCA
CRP
RFX6
TNFRSF1A
NEDD9
SLC22A3
LMTK2
IRS2
TTC9
FRK

ESR2
NR3C1
SRC
8-Mar
MSN
IL6
RHOA
NBN
IL4I1
RPTOR
CDK11B
RET
SPOP
CTNNB1
CDK5RAP2
CTC1
DBN1
ETV7
PIAS2
CGB5
XPR1
REV3L
FGFR4
PAWR
HSP90AA1
BRD2
ERBB2
DAPK2
PLXNB1
COL18A1
ITGA9
SLC1A2
FGF9
XPO1
MAPK14
CCL2
PKHD1
FGFR2
NDUFS2
MDM4
PDLIM5
HMGCR
ALDH9A1
NKX3-1
APC
SLC41A1
MTHFR
UGT2B15
PROM1
SPINK5
NRIP1
MUTYH
IRAK4
TLR1
TNS3
SLC9C2
APOC3
ASNA1
UNC5D
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Table 31: The list of variant-driven genes obtained by the proposed framework for breast
cancer.
RPS6KB1
ESR1
PRDX1
IMMT
BRCA1
SYK
TRIM25
NFKBIA
PPM1G
NOX5
POU5F1
MIR200C
PIK3CB
GRIN1
VAV1
LMNA
PAK1
CSF1
PTPRJ
POT1
CSF2RA
FOXA1
GRHL3
PRKAB1
CASP2
FOXL2
BAIAP2
MR1
BCAR1
TLK2
WEE1
HDAC1
GJB1
IRF8
MAP1LC3A
RAB1A
RPL27A
NOTCH1
YIPF5
CALR
TIPRL
DCN
WWOX
MED14
ADA2
VRK3
MAPKAPK2
SENP1
RAB8A
ABCB1
ERCC1
APOB
TCF4
MLH1
RAD51B
UGT1A1
MSH2

CHEK1
HRAS
USP1
GPR132
MIR10B
GTF2B
HPR
RAB11A
PLD2
DECR1
SELENBP1
DHX58
KCNQ2
AKT2
FBXO28
ARF6
CDC42
AKIP1
ADCY1
EEA1
FBXW7
GJA1
TP73
PXN
BECN1
CDK4
TRPV1
PPARG
LAMB1
GHR
AGO1
AMELX
RYR1
SCRIB
GNAS
RAB6A
PADI4
CAMK2G
RABAC1
MAPK8IP1
GLS
CSF1R
CSNK2A1
PRPF4B
CDK9
NRP1
USF1
NOTCH3
RAB10
POU1F1
NAT2
STAT1
XRCC1
KCNE1
GFAP
APOE
LDLR

PIK3CA
CAV1
AKT1
EPCAM
MTHFR
ELK1
CD44
RHOC
PIK3CD
ADARB1
SEPHS1
CDH1
CD36
POLG
RAF1
PTPN18
TRPV4
FLT4
LDLRAP1
PAFAH1B1
JAK2
PTK2
CFL1
SIRT6
OCRL
BDKRB1
ATF1
ARSB
STARD8
TUBB3
TDP1
ITCH
NSF
DLC1
PLP1
RAB2A
MUC5AC
DDX23
SRGAP2
KCNJ2
PMP22
MUT
CCNB1
EPO
EIF2AK3
PRRT2
CPT1A
PSEN1
ARF4
GATA3
ACTN4
MUTYH
XPA
NOD2
KLHDC7A
COMT
WDR43

STAT3
RAC1
PTEN
RHOA
TLN2
MMP14
CASP8
MAPK14
STIM1
PRNP
TYRP1
NUTF2
MDM2
HFM1
GPNMB
PSTPIP1
KCNJ11
RAB27A
ADCY2
BCL2
MYC
RIN1
GRIA1
FOXO3
MIEN1
YAP1
LMAN1
RBBP8
RDX
TSC22D3
NEDD8
NEDD4L
PLEK
APAF1
CD24
AURKA
NQO1
RAB22A
PDCD10
NEDD4
MAPK8IP3
MAPK1
SIRT1
SMAD4
PTK2B
MIB1
CDKN1A
FAAH
HSPB1
USF3
NRAS
CLDN1
CASR
CYP2E1
XRCC2
CYP2C19
CUX1

TGM2
PARP1
TAZ
PRL
SRC
PIK3CG
SKP2
ABL1
KEAP1
HIF1A
SOD2
ERBB2
RELA
IL1B
FGFR2
PTPN11
ADAM17
TOX3
SCN2A
BST2
BMPR1B
ARHGEF1
RAN
MAP2K6
CYB5A
IKBKE
FHIT
TGFB1
EZH2
KMT2C
NR4A2
MAP2K5
GAS7
DICER1
ARRB2
RAB24
SMAD3
HSP90AA1
BAX
CCND1
HSP90AB1 RRM1
PKD2
MSN
SH3BP4
ACAP1
LOX
RAB7B
SMN2
MED12
SFTPC
TRIO
UQCRHL
ADAM10
RNF213
ABCE1
APP
GAPDH
LGALS4
APC2
NAE1
PRKDC
TOP1
MTA1
FGF2
AKAP10
RND1
S100A4
STARD13
TRPM7
INS
HEBP1
RAB34
FMR1
ZAR1
CSNK1G1
TERT
GRB2
FANCA
TOE1
CMTR1
DHX15
RAC3
NCK2
PRRX1
KLF4
RNPEP
ACE
TPT1
RAB35
KAT5
ESRP2
TGFBR1
PARD6A
MTA3
NUMB
SEC24D
SVIL
CYP2D6
SLX4
STK11
FGFR1
NBN
GALNT12
PALB2
ATR
MEN1
SEMA3F
PHLDA3
ABCC1
AGTR1
SF3B1
ETV6
VDR

EGFR
CTCF
EIF2S1
TP53
ANO1
MAPK8
ATM
CTNNB1
PGR
EIF2AK4
AR
BRCA2
ZHX2
RALGDS
PIN1
STAT5A
NOS3
PRKAA1
SLC9A1
ARF1
BCR
BRK1
PKD1
CACNA1B
NME1
RAB5A
PAK4
TF
PA2G4
NUB1
MAP3K1
MAP2K4
MIR34A
SELENOW
SLC5A5
MST1R
MTOR
CREB1
MME
BARD1
FOXP3
LCK
EZR
UMOD
ACAP2
ASAP1
PCNA
AZIN1
CDKN2A
PLD1
TIAM1
FGF14
ADAMTS15 UIMC1
DNAH8
FANCI
IL4R
SPHK1
AXIN1
COPS6
ZNF217
ZNF516
MTA2
POLR3K
RIOK2
FANCD2
GPI
ABCG2
RIC8A
PIK3C3
CRH
CRHR1
DHX16
RAB7A
TALDO1
ERN1
DRG1
SYVN1
ESS2
P2RY2
GAB1
KRT15
ATL3
RHOQ
PLK4
COIL
ATAT1
CDK1
PON1
ARL4A
SPRY2
CTTN
BMP15
ERBB3
NANOG
RAB23
RUNX2
ARL8B
SDHB
SDHD
KCNQ1
ERCC2
ABCB6
MCM8
PDGFRA
VPS35
SLCO1B1
CTLA4
U2AF1
SCN1A
FAM20A
BRIP1
RET
COL1A1

TRIM28
FXYD1
PSMD5
MST1
EHMT2
PARD3
NCK1
GSK3B
GUCY2F
PICK1
TRIM62
CHEK2
PDP1
MASTL
RAD51
PAK2
PRKCE
HSF1
SH2B1
ZNF135
FGFR4
GRHL1
KRAS
CA1
PPP2R1A
L3MBTL3
AMOTL1
NEDD9
CFTR
DNMT3A
CTBP2
CKLF
CA2
HIVEP3
RAB33B
PTPRF
HEY1
RAB4A
GALNT6
VIM
RNASE1
LINC00310
TET1
PRKCA
CHD1
SMURF2
STAT2
FIP1L1
BABAM2
LEPR
ERBB4
ABCC11
CYP2C8
MMP2
PITX2
CELSR2
NA
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Table 32: The complete list of variant-disease pairs identified by the proposed method and
the baseline method from the gold standard databases [29].
PMID

Mutation

Gold_standard

Proposed_method

Co-occurrence method

12023985 p|SUB|R|188|H

breast neoplasms

breast cancer

breast cancer

12100746 p|SUB|V|89|L

breast neoplasms

breast cancer

breast cancer

12516098 p|SUB|P|1315|L

breast neoplasms

breast cancer

breast cancer

12602915 p|SUB|R|726|L

breast neoplasms

prostate cancer

prostate cancer

12628588 p|SUB|Q|253|H

breast neoplasms

breast cancer

breast cancer

12702523 p|SUB|R|72|P

breast neoplasms

breast cancer

breast cancer

12786840 p|SUB|R|156|G

breast neoplasms

breast carcinoma

breast carcinoma

12810666 p|SUB|L|1420|F

breast neoplasms, ovarian neoplasms

breast cancer

breast cancer

12872252 p|SUB|Q|540|L

breast neoplasms, ovarian neoplasms

breast cancer

breast cancer

12917204 p|SUB|L|546|V

breast neoplasms

breast cancer

breast cancer

14683420 p|SUB|R|72|P

breast neoplasms

breast cancer

breast cancer

15059511 p|SUB|P|359|L

breast neoplasms

breast cancer

breast cancer

15170666 p|SUB|E|233|G

breast neoplasms

breast cancer

breast cancer

16061562 p|SUB|C|645|R

breast neoplasms, ovarian neoplasms

ovarian tumor

ovarian tumor

16168123 p|SUB|S|384|F

breast neoplasms

breast cancer

breast cancer

16333312 p|SUB|V|507|M

breast neoplasms, ovarian neoplasms

breast cancer

breast cancer

16652348 c|SUB|C|146|G

breast neoplasms

breast cancer

breast cancer

16760288 p|SUB|F|486|L

breast neoplasms, ovarian neoplasms

breast cancer

breast cancer

16760288 p|SUB|N|550|H

breast neoplasms, ovarian neoplasms

breast cancer

breast cancer

16760288 p|SUB|Y|179|C

breast neoplasms, ovarian neoplasms

breast cancer

breast cancer

16822847 p|SUB|G|388|R

breast neoplasms

breast cancer

breast cancer

16825437 p|SUB|S|558|P

breast neoplasms

breast cancer

breast cancer

17001622 p|SUB|V|2424|G

breast neoplasms

breast cancer

breast cancer

17217814 p|SUB|V|158|M

breast neoplasms

breast cancer

breast cancer

17427234 p|SUB|R|248|W

neuroblastoma, li-fraumeni syndrome

neuroblastoma

neuroblastoma

17541742 p|SUB|R|213|Q

breast neoplasms, ovarian neoplasms

li-fraumeni syndrome

li-fraumeni syndrome

17541742 p|SUB|R|290|H

breast neoplasms, ovarian neoplasms

li-fraumeni-like

li-fraumeni-like

17553133 p|SUB|K|303|R

breast neoplasms

breast cancer

breast cancer

17574969 p|SUB|R|1699|W

phyllodes tumor

tumor of the breast

tumor of the breast

breast neoplasms, ovarian neoplasms,

endometrial tumors

endometrial tumors

endometrial tumors

endometrial tumors

17848578 p|SUB|Q|564|H

endometrial tumors
17848578 p|SUB|V|695|L

breast neoplasms, ovarian neoplasms,
endometrial tumors

18241035 p|SUB|D|301|H

breast neoplasms

breast cancers

breast cancers

18241035 p|SUB|G|479|E

breast neoplasms

breast cancers

breast cancers

18241035 p|SUB|L|792|F

breast neoplasms

breast cancers

breast cancers
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18565893 p|SUB|S|707|P

breast neoplasms, thyroid neoplasms,

breast cancer

breast cancer

ENDOCRINE GLAND NEOPLASMS
10477429 p|SUB|M|133|T

breast neoplasms, li-fraumeni syndrome

breast sarcoma

NA

10485478 p|SUB|G|1449|V

breast neoplasms, hepatocellular

breast cancers

NA

breast cancers

NA

breast cancers

NA

breast cancers

NA

carcinoma
10485478 p|SUB|G|1464|E

breast neoplasms, hepatocellular
carcinoma

10485478 p|SUB|I|1572|T

breast neoplasms, hepatocellular
carcinoma

10485478 p|SUB|Q|1445|H

breast neoplasms, hepatocellular
carcinoma

10534763 p|SUB|G|2765|S

breast neoplasms

breast cancer

NA

10547570 p|SUB|R|273|C

phyllodes tumor

phyllodes tumours

NA

11212236 p|SUB|L|452|M

breast neoplasms

breast tumor

NA

11212236 p|SUB|N|435|S

breast neoplasms

breast tumor

NA

11212236 p|SUB|V|387|M

breast neoplasms

breast tumor

NA

11212236 p|SUB|V|447|A

breast neoplasms

breast tumor

NA

12100746 p|SUB|A|49|T

breast neoplasms

breast cancer

NA

12645254 p|SUB|M|1652|I

breast neoplasms, ovarian neoplasms

ovarian cancer

NA

12645254 p|SUB|S|1613|G

breast neoplasms, ovarian neoplasms

ovarian cancer

NA

12645254 p|SUB|W|1837|R

breast neoplasms, ovarian neoplasms

ovarian cancer

NA

12649339 p|SUB|S|215|I

breast neoplasms

breast cancer

NA

12668615 p|SUB|D|213|N

breast neoplasms

breast cancer

NA

12872252 p|SUB|V|524|I

breast neoplasms, ovarian neoplasms

breast cancer

NA

15059511 p|SUB|N|289|H

breast neoplasms

breast cancer

NA

15059511 p|SUB|N|371|H

breast neoplasms

breast cancer

NA

15059511 p|SUB|N|991|D

breast neoplasms

breast cancer

NA

15101044 c|SUB|T|2572|C

breast neoplasms

breast cancer

NA

15101044 p|SUB|P|1054|R

breast neoplasms

breast cancer

NA

15235021 p|SUB|R|732|Q

stomach neoplasms, breast neoplasms

breast cancers

NA

15235021 p|SUB|W|409|R

stomach neoplasms, breast neoplasms

breast cancers

NA

15649950 p|SUB|P|85|L

breast neoplasms

breast cancer

NA

15665273 p|SUB|S|148|A

breast neoplasms

breast cancer

NA

15665273 p|SUB|S|251|A

breast neoplasms

breast cancer

NA

15665273 p|SUB|S|288|A

breast neoplasms

breast cancer

NA

15870154 p|SUB|T|461|D

breast neoplasms

breast cancer

NA

16061562 p|SUB|C|557|S

ovarian neoplasms

ovarian tumour

NA

16061562 p|SUB|I|738|V

breast neoplasms

ovarian tumour

NA

16061562 p|SUB|S|761|N

breast neoplasms, uterine neoplasms

ovarian tumours

NA
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16123141 p|SUB|T|135|E

breast neoplasms

breast cancer

NA

16280053 p|SUB|P|47|A

breast neoplasms

breast cancer

NA

16503999 p|SUB|C|282|Y

breast neoplasms

breast cancer

NA

16563154 c|SUB|T|309|G

breast neoplasms

breast cancer

NA

16652348 p|SUB|F|858|L

breast neoplasms

breast cancer

NA

16969499 p|SUB|S|1841|N

breast neoplasms, ovarian neoplasms

breast tumorigenesis

NA

17130833 p|SUB|V|143|A

breast neoplasms

breast cancer

NA

17317153 p|SUB|P|871|L

breast neoplasms

breast cancers

NA

breast neoplasms, ovarian neoplasms

hereditary

NA

17493881 p|SUB|V|1833|M

breast/ovarian cancer
17531442 p|SUB|S|1143|A

breast neoplasms

breast cancer

NA

17531442 p|SUB|S|1280|A

breast neoplasms

breast cancer

NA

17550384 p|SUB|P|350|R

breast carcinoma, colorectal neoplasms,

breast carcinoma

NA

breast carcinoma

NA

non-small-cell lung carcinoma, gastric
carcinoma
17550384 p|SUB|R|389|C

breast carcinoma, colorectal neoplasms,
non-small-cell lung carcinoma, gastric
carcinoma

17889706 p|SUB|S|255|R

breast neoplasms

breast tumors

NA

18036263 p|SUB|A|1708|V

breast neoplasms

breast cancer

NA

18036263 p|SUB|G|1738|R

breast neoplasms

breast cancer

NA

18036263 p|SUB|R|1699|Q

breast neoplasms

breast cancer

NA

18083510 p|SUB|A|238|V

breast neoplasms

ovarian cancer

NA

18083510 p|SUB|R|259|H

breast neoplasms

ovarian cancer

NA

18083510 p|SUB|S|313|G

breast neoplasms

ovarian cancer

NA

18186519 p|SUB|G|12|S

breast neoplasms, colon neoplasms

colon and breast cancer

NA

18186519 p|SUB|G|12|V

breast neoplasms, colon neoplasms

colon and breast cancer

NA

18186519 p|SUB|V|600|E

breast neoplasms, colon neoplasms

colon and breast cancer

NA

18307025 p|SUB|Y|220|C

osteosarcoma, breast neoplasms, colon

malignant tumors

NA

neoplasms, malignant fibrous
histiocytoma, lung neoplasms
18332865 p|SUB|C|124|S

breast neoplasms

breast cancer

NA

18332865 p|SUB|G|129|E

breast neoplasms

breast cancer

NA

18372405 p|SUB|A|111|D

breast neoplasms

breast cancer

NA

18372405 p|SUB|G|160|R

breast neoplasms

breast cancer

NA

18375489 p|SUB|E|542|K

breast neoplasms, colorectal neoplasms,

colorectal cancer

NA

lung neoplasms, melanoma
18431743 p|SUB|F|31|I

ovarian neoplasms

breast cancer

NA

18431743 p|SUB|N|372|H

ovarian neoplasms

breast cancer

NA
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18558293 p|SUB|A|39|P

multiple hamartoma syndrome, breast

gastric malignant

neoplasms, thyroid neoplasms,

lymphoma

NA

lymphoma
9407971

p|SUB|R|175|H

breast neoplasms

breast cancer

NA

9407971

p|SUB|R|249|S

breast neoplasms

breast cancer

NA

9407971

p|SUB|R|273|H

breast neoplasms

breast cancer

NA

9806478

p|SUB|A|148|T

melanoma

melanoma

NA
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Table 33: The complete list of variants automatically extracted from 10,000 random articles and also manually reviewed and validated. False positive means the extracted entity
is not a variant and it is wrongly identified as a variant.
PMCID

NORMALIZED_FORM

TYPE

MENTIONED

FALSE POSITIVE?

PMC4502233

p|SUB|R|4810|K

ProteinMutation

p.R4810K

NO

PMC4565919

p|SUB|L|90|M

ProteinMutation

L90M

NO

PMC4876505

c|SUB|G|93|A

DNAMutation

G93A

NO

PMC2684265

p|SUB|P|504|S

ProteinMutation

P504S

NO

PMC3666908

p|SUB|V|158|M

ProteinMutation

Val158Met

NO

PMC4718276

p|SUB|V|600|E

ProteinMutation

V600E

NO

PMC4962770

p|SUB|V|66|M

ProteinMutation

Val66Met

NO

PMC4991467

rs6295

SNP

rs6295

NO

PMC5012569

p|SUB|P|301|S

ProteinMutation

P301S

NO

PMC1247523

c|SUB|G|1800|A

DNAMutation

G1800A

YES

PMC2188802

c|SUB|C|200|T

DNAMutation

C/T200

YES

PMC2584175

c|SUB|A|1|C

DNAMutation

A1C

YES

PMC2720913

p|SUB|E||T

ProteinMutation

E/T

YES

PMC2829413

c|SUB|A|1|C

DNAMutation

A1C

YES

PMC2841238

c|SUB|G|1311|A

DNAMutation

G1311A

YES

PMC2841238

c|SUB|G|1329|A

DNAMutation

G1329A

YES

PMC2841238

c|SUB|G|1379|A

DNAMutation

G1379A

YES

PMC2841238

c|SUB|G|1316|A

DNAMutation

G1316A

YES

PMC2875450

c|SUB|A|1|C

DNAMutation

A1C

YES

PMC2889782

c|SUB|A|1|C

DNAMutation

A1C

YES

PMC2915039

p|SUB|H|14|A

ProteinMutation

H14A

YES

PMC2915039

p|SUB|H|14|C

ProteinMutation

H14C

YES

PMC2959805

p|SUB|H|11|A

ProteinMutation

H11A

YES

PMC2968464

p|SUB|H|11|A

ProteinMutation

H11A

YES

PMC2968464

p|SUB|H|11|C

ProteinMutation

H11C

YES

PMC2968464

p|SUB|H|12|A

ProteinMutation

H12A

YES

PMC2968464

p|SUB|H|12|C

ProteinMutation

H12C

YES

PMC2968899

p|SUB|H|10|A

ProteinMutation

H10A

YES

PMC2969907

p|SUB|H|23|A

ProteinMutation

H23A

YES

PMC2969907

p|SUB|H|14|A

ProteinMutation

H14A

YES

PMC2969907

p|SUB|H|20|A

ProteinMutation

H20A

YES

PMC2969907

p|SUB|H|26|A

ProteinMutation

H26A

YES

PMC2969907

p|SUB|H|18|A

ProteinMutation

H18A

YES

PMC2969907

p|SUB|H|29|A

ProteinMutation

H29A

YES

PMC2969907

p|SUB|H|28|A

ProteinMutation

H28A

YES
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PMC2969907

p|SUB|H|19|A

ProteinMutation

H19A

YES

PMC2969907

p|SUB|H|22|A

ProteinMutation

H22A

YES

PMC2969907

p|SUB|H|22|C

ProteinMutation

H22C

YES

PMC2969907

p|SUB|H|27|A

ProteinMutation

H27A

YES

PMC2969907

p|SUB|H|13|A

ProteinMutation

H13A

YES

PMC2969907

p|SUB|H|11|A

ProteinMutation

H11A

YES

PMC2969907

p|SUB|H|12|A

ProteinMutation

H12A

YES

PMC2969907

p|SUB|H|31|A

ProteinMutation

H31A

YES

PMC2969907

p|SUB|H|31|C

ProteinMutation

H31C

YES

PMC2979928

p|SUB|H|11|A

ProteinMutation

H11A

YES

PMC2979928

p|SUB|H|14|A

ProteinMutation

H14A

YES

PMC2979928

p|SUB|H|14|C

ProteinMutation

H14C

YES

PMC2979928

p|SUB|H|15|A

ProteinMutation

H15A

YES

PMC2979928

p|SUB|H|15|C

ProteinMutation

H15C

YES

PMC2983608

p|SUB|H|20|A

ProteinMutation

H20A

YES

PMC2983608

p|SUB|H|20|C

ProteinMutation

H20C

YES

PMC2992198

c|SUB|A|1|C

DNAMutation

A1C

YES

PMC3005448

c|SUB|A|1|C

DNAMutation

A1C

YES

PMC3005479

c|SUB|A|1|C

DNAMutation

A1C

YES

PMC3007219

p|SUB|H|13|A

ProteinMutation

H13A

YES

PMC3007219

p|SUB|H|13|C

ProteinMutation

H13C

YES

PMC3007494

p|SUB|H|23|A

ProteinMutation

H23A

YES

PMC3007494

p|SUB|H|24|A

ProteinMutation

H24A

YES

PMC3007494

p|SUB|H|24|C

ProteinMutation

H24C

YES

PMC3007494

p|SUB|H|23|C

ProteinMutation

H23C

YES

PMC3007494

p|SUB|H|23|D

ProteinMutation

H23D

YES

PMC3007494

p|SUB|H|24|D

ProteinMutation

H24D

YES

PMC3007494

p|SUB|H|24|E

ProteinMutation

H24E

YES

PMC3007494

p|SUB|H|24|F

ProteinMutation

H24F

YES

PMC3008083

p|SUB|H|16|A

ProteinMutation

H16A

YES

PMC3008083

p|SUB|H|16|C

ProteinMutation

H16C

YES

PMC3008083

p|SUB|H|17|A

ProteinMutation

H17A

YES

PMC3008083

p|SUB|H|17|C

ProteinMutation

H17C

YES

PMC3008083

p|SUB|H|32|A

ProteinMutation

H32A

YES

PMC3008083

p|SUB|H|32|C

ProteinMutation

H32C

YES

PMC3009229

p|SUB|H|10|A

ProteinMutation

H10A

YES

PMC3009229

p|SUB|H|11|A

ProteinMutation

H11A

YES

PMC3009229

p|SUB|H|11|C

ProteinMutation

H11C

YES

PMC3009229

p|SUB|H|12|A

ProteinMutation

H12A

YES

PMC3009229

p|SUB|H|12|C

ProteinMutation

H12C

YES
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PMC3009229

p|SUB|H|13|A

ProteinMutation

H13A

YES

PMC3009229

p|SUB|H|14|A

ProteinMutation

H14A

YES

PMC3009229

p|SUB|H|14|C

ProteinMutation

H14C

YES

PMC3009229

p|SUB|H|15|A

ProteinMutation

H15A

YES

PMC3009229

p|SUB|H|15|C

ProteinMutation

H15C

YES

PMC3011503

p|SUB|H|10|A

ProteinMutation

H10A

YES

PMC3011503

p|SUB|H|10|C

ProteinMutation

H10C

YES

PMC3011503

p|SUB|H|11|A

ProteinMutation

H11A

YES

PMC3011503

p|SUB|H|11|C

ProteinMutation

H11C

YES

PMC3011503

p|SUB|H|13|A

ProteinMutation

H13A

YES

PMC3011503

p|SUB|H|13|C

ProteinMutation

H13C

YES

PMC3011503

p|SUB|H|14|A

ProteinMutation

H14A

YES

PMC3011503

p|SUB|H|14|C

ProteinMutation

H14C

YES

PMC3011503

p|SUB|H|15|A

ProteinMutation

H15A

YES

PMC3011503

p|SUB|H|15|C

ProteinMutation

H15C

YES

PMC3011503

p|SUB|H|30|A

ProteinMutation

H30A

YES

PMC3011503

p|SUB|H|30|C

ProteinMutation

H30C

YES

PMC3011503

p|SUB|H|31|A

ProteinMutation

H31A

YES

PMC3011503

p|SUB|H|31|C

ProteinMutation

H31C

YES

PMC3011503

p|SUB|H|32|A

ProteinMutation

H32A

YES

PMC3011503

p|SUB|H|32|C

ProteinMutation

H32C

YES

PMC3011503

p|SUB|H|34|A

ProteinMutation

H34A

YES

PMC3011503

p|SUB|H|34|C

ProteinMutation

H34C

YES

PMC3011503

p|SUB|H|35|A

ProteinMutation

H35A

YES

PMC3011503

p|SUB|H|35|C

ProteinMutation

H35C

YES

PMC3011503

p|SUB|H|36|A

ProteinMutation

H36A

YES

PMC3011503

p|SUB|H|36|C

ProteinMutation

H36C

YES

PMC3012188

c|SUB|A|1|C

DNAMutation

A1C

YES

PMC3030744

c|SUB|G|1575|A

DNAMutation

G1575A

YES

PMC3051471

p|SUB|H|31|A

ProteinMutation

H31A

YES

PMC3051471

p|SUB|H|32|A

ProteinMutation

H32A

YES

PMC3051471

p|SUB|H|33|A

ProteinMutation

H33A

YES

PMC3051471

p|SUB|H|34|A

ProteinMutation

H34A

YES

PMC3051517

p|SUB|H|14|A

ProteinMutation

H14A

YES

PMC3051517

p|SUB|H|13|A

ProteinMutation

H13A

YES

PMC3051517

p|SUB|H|12|A

ProteinMutation

H12A

YES

PMC3088031

p|SUB|T|9|S

ProteinMutation

T9S

YES

PMC3122477

c|DEL||

DNAMutation

DELTA

YES

PMC3139590

RS800

SNP

RS800

YES

PMC3164897

5bins

DNAMutation

5 bins

YES
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PMC3164897

3bins

DNAMutation

3 bins

YES

PMC3196552

c|SUB|S|-2600|H

DNAMutation

S-2600H

YES

PMC3202145

c|SUB|C|31|G

DNAMutation

C31G

YES

PMC3225014

c|SUB|GGCA|6|C

DNAMutation

GGCA6C

YES

PMC3225014

c|SUB|CCGT|6|G

DNAMutation

CCGT6G

YES

PMC3275195

p|SUB|H|10|A

ProteinMutation

H10A

YES

PMC3275195

p|SUB|H|11|A

ProteinMutation

H11A

YES

PMC3275195

p|SUB|H|12|A

ProteinMutation

H12A

YES

PMC3275195

p|SUB|H|14|A

ProteinMutation

H14A

YES

PMC3275195

p|SUB|H|16|A

ProteinMutation

H16A

YES

PMC3275195

p|SUB|H|17|A

ProteinMutation

H17A

YES

PMC3275195

p|SUB|H|18|A

ProteinMutation

H18A

YES

PMC3297250

p|SUB|H|13|A

ProteinMutation

H13A

YES

PMC3297250

p|SUB|H|14|A

ProteinMutation

H14A

YES

PMC3353114

p|SUB|D|125|I

ProteinMutation

D 125I

YES

PMC3537756

c|SUB|G|3|A

DNAMutation

G3A

YES

PMC3551769

p|SUB|V|36|G

ProteinMutation

V36G

YES

PMC3588815

p|SUB|H|11|A

ProteinMutation

H11A

YES

PMC3588815

p|SUB|H|12|A

ProteinMutation

H12A

YES

PMC3588815

p|SUB|H|19|A

ProteinMutation

H19A

YES

PMC3588815

p|SUB|H|19|C

ProteinMutation

H19C

YES

PMC3588815

p|SUB|H|20|A

ProteinMutation

H20A

YES

PMC3588815

p|SUB|H|20|C

ProteinMutation

H20C

YES

PMC3588815

p|SUB|H|21|A

ProteinMutation

H21A

YES

PMC3588815

p|SUB|H|21|C

ProteinMutation

H21C

YES

PMC3598566

p|SUB|V|150|T

ProteinMutation

150 V/T

YES

PMC3721223

g|SUB|A|80915|G

DNAMutation

A80915G

YES

PMC3841629

c|SUB|A|1|C

DNAMutation

A1C

YES

PMC3868173

MOT>LUM

ProteinMutation

MOT >LUM

YES

PMC3881066

p|SUB|A|30|P

ProteinMutation

A30P

YES

PMC3927678

p|SUB|H|379|UF

ProteinMutation

H 379 UF

YES

PMC3949696

c|SUB|A|1|C

DNAMutation

A1C

YES

PMC3998480

p|SUB|H|12|A

ProteinMutation

H12A

YES

PMC4013063

p|SUB|M|20|A

ProteinMutation

M20A

YES

PMC4013537

c|SUB|A|1|C

DNAMutation

A1C

YES

PMC4023268

c|SUB|A|86|C

DNAMutation

A86C

YES

PMC4051029

p|SUB|H|12|A

ProteinMutation

H12A

YES

PMC4051064

p|SUB|H|10|A

ProteinMutation

H10A

YES

PMC4051064

p|SUB|H|10|C

ProteinMutation

H10C

YES

PMC4051064

p|SUB|H|11|A

ProteinMutation

H11A

YES
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PMC4051064

p|SUB|H|11|C

ProteinMutation

H11C

YES

PMC4051064

p|SUB|H|12|A

ProteinMutation

H12A

YES

PMC4051064

p|SUB|H|13|A

ProteinMutation

H13A

YES

PMC4051064

p|SUB|H|16|A

ProteinMutation

H16A

YES

PMC4051064

p|SUB|H|16|C

ProteinMutation

H16C

YES

PMC4051064

p|SUB|H|17|A

ProteinMutation

H17A

YES

PMC4051064

p|SUB|H|17|C

ProteinMutation

H17C

YES

PMC4051064

p|SUB|H|18|A

ProteinMutation

H18A

YES

PMC4051064

p|SUB|H|18|C

ProteinMutation

H18C

YES

PMC4051074

c|SUB|C|28|A

DNAMutation

C28A

YES

PMC4051074

p|SUB|H|10|A

ProteinMutation

H10A

YES

PMC4051074

c|SUB|C|11|A

DNAMutation

C11A

YES

PMC4051074

p|SUB|H|26|A

ProteinMutation

H26A

YES

PMC4051074

p|SUB|H|27|A

ProteinMutation

H27A

YES

PMC4051074

c|SUB|C|29|A

DNAMutation

C29A

YES

PMC4051074

p|SUB|H|29|A

ProteinMutation

H29A

YES

PMC4051074

c|SUB|C|30|A

DNAMutation

C30A

YES

PMC4051074

p|SUB|H|30|A

ProteinMutation

H30A

YES

PMC4051074

c|SUB|C|31|A

DNAMutation

C31A

YES

PMC4051074

p|SUB|H|31|A

ProteinMutation

H31A

YES

PMC4051074

c|SUB|C|32|A

DNAMutation

C32A

YES

PMC4051074

p|SUB|H|32|A

ProteinMutation

H32A

YES

PMC4051074

p|SUB|H|33|A

ProteinMutation

H33A

YES

PMC4139185

p|SUB|C|13|N

ProteinMutation

C13 N

YES

PMC4153077

p|SUB|A|16|S

ProteinMutation

A 16S

YES

PMC4257264

p|SUB|N|11|C

ProteinMutation

N11C

YES

PMC4257264

c|SUB|C|11|A

DNAMutation

C11A

YES

PMC4257264

c|SUB|C|5|A

DNAMutation

C5A

YES

PMC4257264

p|SUB|N|11|D

ProteinMutation

N11D

YES

PMC4257264

c|SUB|C|6|A

DNAMutation

C6A

YES

PMC4257264

p|SUB|H|11|A

ProteinMutation

H11A

YES

PMC4257264

p|SUB|H|11|C

ProteinMutation

H11C

YES

PMC4257264

p|SUB|H|12|C

ProteinMutation

H12C

YES

PMC4257264

p|SUB|H|13|C

ProteinMutation

H13C

YES

PMC4257264

p|SUB|H|21|C

ProteinMutation

H21C

YES

PMC4257264

p|SUB|H|31|C

ProteinMutation

H31C

YES

PMC4257264

p|SUB|H|32|C

ProteinMutation

H32C

YES

PMC4257264

p|SUB|H|41|C

ProteinMutation

H41C

YES

PMC4257264

p|SUB|H|42|C

ProteinMutation

H42C

YES

PMC4257264

p|SUB|H|51|C

ProteinMutation

H51C

YES
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PMC4257264

p|SUB|H|52|C

ProteinMutation

H52C

YES

PMC4257264

p|SUB|H|12|D

ProteinMutation

H12D

YES

PMC4257264

p|SUB|H|11|D

ProteinMutation

H11D

YES

PMC4257264

p|SUB|H|21|D

ProteinMutation

H21D

YES

PMC4257264

p|SUB|H|13|D

ProteinMutation

H13D

YES

PMC4257264

p|SUB|H|14|D

ProteinMutation

H14D

YES

PMC4257264

p|SUB|H|31|D

ProteinMutation

H31D

YES

PMC4257264

p|SUB|H|32|D

ProteinMutation

H32D

YES

PMC4257264

p|SUB|H|41|D

ProteinMutation

H41D

YES

PMC4257264

p|SUB|H|42|D

ProteinMutation

H42D

YES

PMC4257264

p|SUB|H|51|D

ProteinMutation

H51D

YES

PMC4257264

p|SUB|H|52|D

ProteinMutation

H52D

YES

PMC4320108

p|SUB|T|17|N

ProteinMutation

T17N

YES

PMC4327586

p|SUB|S|010111|C

ProteinMutation

S010111C

YES

PMC4329618

c|SUB|G|1322|A

DNAMutation

G1322A

YES

PMC4329618

c|SUB|G|1312|A

DNAMutation

G1312A

YES

PMC4329618

c|SUB|G|1367|C

DNAMutation

G1367C

YES

PMC4329618

c|SUB|G|1316|A

DNAMutation

G1316A

YES

PMC4370234

p.136]

ProteinMutation

p. 136]

YES

PMC4372839

p|SUB|E|200|V

ProteinMutation

E200V

YES

PMC4378971

c|SUB|T||C

DNAMutation

T/C

YES

PMC4384578

p|SUB|H|10|A

ProteinMutation

H10A

YES

PMC4384578

p|SUB|H|10|C

ProteinMutation

H10C

YES

PMC4384578

p|SUB|H|11|A

ProteinMutation

H11A

YES

PMC4384578

p|SUB|H|11|C

ProteinMutation

H11C

YES

PMC4384578

p|SUB|H|12|A

ProteinMutation

H12A

YES

PMC4384578

p|SUB|H|12|C

ProteinMutation

H12C

YES

PMC4384578

p|SUB|H|13|C

ProteinMutation

H13C

YES

PMC4384578

p|SUB|H|13|D

ProteinMutation

H13D

YES

PMC4384578

p|SUB|H|13|E

ProteinMutation

H13E

YES

PMC4384578

p|SUB|H|13|F

ProteinMutation

H13F

YES

PMC4384578

p|SUB|H|13|A

ProteinMutation

H13A

YES

PMC4433076

c|SUB|A|1|C

DNAMutation

A1C

YES

PMC4439532

c|SUB|A|1|C

DNAMutation

A1C

YES

PMC4462250

p|SUB|L||T

ProteinMutation

L/T

YES

PMC4465688

c|SUB|C|3|G

DNAMutation

C3G

YES

PMC4513483

p|SUB|A|10|V

ProteinMutation

A10 V

YES

PMC4517832

c|SUB|C|-46|A

DNAMutation

C-46A

YES

PMC4530960

c|SUB|A|7|T

DNAMutation

A 7T

YES

PMC4592593

c|SUB|GC|-9|A

DNAMutation

GC-9A

YES

63

PMC4631937

p|SUB|P|2714|H

ProteinMutation

P2714H

YES

PMC4644923

p|SUB|G|12|L

ProteinMutation

G12L

YES

PMC4644923

p|SUB|G|12|H

ProteinMutation

G12H

YES

PMC4644923

p|SUB|G|30|L

ProteinMutation

G30L

YES

PMC4644923

p|SUB|H|23|R

ProteinMutation

H23R

YES

PMC4682137

p|SUB|R|6|G

ProteinMutation

R6G

YES

PMC4719921

p|SUB|H|21|A

ProteinMutation

H21A

YES

PMC4719921

p|SUB|H|21|C

ProteinMutation

H21C

YES

PMC4719921

p|SUB|H|22|A

ProteinMutation

H22A

YES

PMC4719921

p|SUB|H|22|C

ProteinMutation

H22C

YES

PMC4719921

p|SUB|H|43|A

ProteinMutation

H43A

YES

PMC4719921

p|SUB|H|43|C

ProteinMutation

H43C

YES

PMC4719921

p|SUB|H|44|A

ProteinMutation

H44A

YES

PMC4719921

p|SUB|H|44|C

ProteinMutation

H44C

YES

PMC4745523

p|SUB|G|25|N

ProteinMutation

G25N

YES

PMC4772241

c|SUB|T|2|C

DNAMutation

T2C

YES

PMC4840265

c|SUB|TC|-202|A

DNAMutation

TC-202A

YES

PMC4851292

p|SUB|S|25|N

ProteinMutation

S25N

YES

PMC4971855

p|SUB|H|13|A

ProteinMutation

H13A

YES

PMC4971855

p|SUB|H|14|A

ProteinMutation

H14A

YES

PMC4971855

p|SUB|H|31|A

ProteinMutation

H31A

YES

PMC4971855

p|SUB|H|31|C

ProteinMutation

H31C

YES

PMC5055046

c|SUB|C|10|AA

DNAMutation

C10AA

YES

PMC5055046

c|SUB|C|09|A

DNAMutation

C09A

YES

PMC5055046

c|SUB|A|1|C

DNAMutation

A1C

YES

PMC5059018

p|SUB|V|103|C

ProteinMutation

V103C

YES

PMC5088442

c|SUB|A|41|G

DNAMutation

A 41G

YES

PMC5118020

p|SUB|T|40|S

ProteinMutation

T40S

YES

[19] [22] [51] [52] [53]

YES

PMC5119779

c|DUP|[19||[22][51][52][53][54][55]
DNAMutation

[54] [55]
PMC5146877

p|SUB|Q|1000|P

ProteinMutation

Q1000P

YES

PMC5244540

c|SUB|A|2|C

DNAMutation

A2 to C

YES

PMC5290578

p|SUB|H|10|A

ProteinMutation

H10A

YES

PMC5290578

p|SUB|S|2|C

ProteinMutation

S2C

YES

PMC5290578

p|SUB|H|11|A

ProteinMutation

H11A

YES

PMC5290578

p|SUB|H|12|A

ProteinMutation

H12A

YES

PMC5290578

p|SUB|H|13|A

ProteinMutation

H13A

YES

PMC5290578

p|SUB|H|13|C

ProteinMutation

H13C

YES

PMC5319737

c|SUB|CT|-90|A

DNAMutation

CT-90A

YES

PMC5319737

c|SUB|CT|90|A

DNAMutation

CT90A

YES

64

PMC5357070

c|SUB|A|1|C

DNAMutation

A1C

YES

PMC5409166

c|SUB|A|1|C

DNAMutation

A1C

YES

PMC5466104

p|SUB|K|550|X

ProteinMutation

K550X

YES

PMC5523872

p|SUB|T|28|N

ProteinMutation

T28N

YES

PMC5523872

p|SUB|T|27|N

ProteinMutation

T27N

YES

PMC5523872

p|SUB|T|37|N

ProteinMutation

T37N

YES

PMC5603897

p|SUB|M|062|X

ProteinMutation

M062X

YES

PMC5631406

c|SUB|C||T

DNAMutation

C/T

YES

PMC5657054

|SUB|DIS|2001|SEP

ProteinMutation

Dis 2001 Sep

YES

PMC56607

|[||76

DNAMutation

[76]

YES
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In spite of the efforts in developing and maintaining accurate variant databases, a large
number of disease-associated variants are still hidden in the biomedical literature. Curation of the biomedical literature in an effort to extract this information is a challenging
task due to i) the complexity of natural language processing, ii) inconsistent use of standard recommendations for variant description, and iii) the lack of clarity and consistency
in describing the variant-genotype-phenotype associations in the biomedical literature. In
this article, we employ text mining and word cloud analysis techniques to address these
challenges. The proposed framework extracts the variant-gene-disease associations from
the full-length biomedical literature and designs an evidence-based variant-driven gene
panel for a given condition. We validate the identified genes by showing their diagnostic abilities to predict the patients’ clinical outcomes on several independent validation
cohorts. As representative examples, we present our results for acute myeloid leukemia
(AML), breast cancer, and prostate cancer. We compare these panels with other variantdriven gene panels obtained from Clinvar, Mastermind, and others from literature, as well
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as with a panel identified with a classical differentially expressed genes (DEGs) approach.
The results show that the panels obtained by the proposed framework yield better results
than the other gene panels currently available in the literature.
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